Next Article in Journal
ZEB2, the Mowat-Wilson Syndrome Transcription Factor: Confirmations, Novel Functions, and Continuing Surprises
Next Article in Special Issue
Pseudogene Transcripts in Head and Neck Cancer: Literature Review and In Silico Analysis
Previous Article in Journal
Retinoic Acid-Induced Gene G(RIG-G) as a Novel Monitoring Biomarker in Leukemia and Its Clinical Applications
Previous Article in Special Issue
Deciphering the Variants Located in the MIR196A2, MIR146A, and MIR423 with Type-2 Diabetes Mellitus in Pakistani Population
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 12
Issue 7
10.3390/genes12071036
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Roles of ncRNAs as ceRNAs in Gastric Cancer

by
Junhong Ye
1,
Jifu Li
2 and
Ping Zhao
1,*
1
State Key Laboratory of Silkworm Genome Biology, Biological Science Research Center, Southwest University, Chongqing 400716, China
2
College of Sericulture, Textile and Biomass Sciences, Southwest University, Chongqing 400716, China
*
Author to whom correspondence should be addressed.
Genes 2021, 12(7), 1036; https://doi.org/10.3390/genes12071036
Submission received: 25 May 2021 / Revised: 28 June 2021 / Accepted: 28 June 2021 / Published: 2 July 2021
(This article belongs to the Special Issue Non-coding RNAs in Human Health and Diseases)
Browse Figures
Versions Notes

Abstract

:
Although ignored in the past, with the recent deepening of research, significant progress has been made in the field of non-coding RNAs (ncRNAs). Accumulating evidence has revealed that microRNA (miRNA) response elements regulate RNA. Long ncRNAs, circular RNAs, pseudogenes, miRNAs, and messenger RNAs (mRNAs) form a competitive endogenous RNA (ceRNA) network that plays an essential role in cancer and cardiovascular, neurodegenerative, and autoimmune diseases. Gastric cancer (GC) is one of the most common cancers, with a high degree of malignancy. Considerable progress has been made in understanding the molecular mechanism and treatment of GC, but GC’s mortality rate is still high. Studies have shown a complex ceRNA crosstalk mechanism in GC. lncRNAs, circRNAs, and pseudogenes can interact with miRNAs to affect mRNA transcription. The study of the involvement of ceRNA in GC could improve our understanding of GC and lead to the identification of potential effective therapeutic targets. The research strategy for ceRNA is mainly to screen the different miRNAs, lncRNAs, circRNAs, pseudogenes, and mRNAs in each sample through microarray or sequencing technology, predict the ceRNA regulatory network, and, finally, conduct functional research on ceRNA. In this review, we briefly discuss the proposal and development of the ceRNA hypothesis and the biological function and principle of ceRNAs in GC, and briefly introduce the role of ncRNAs in the GC’s ceRNA network.

1. Introduction

A non-coding RNA (ncRNA) is a type of RNA that does not have the function of a coding protein [1]. NcRNAs, which account for 98% of the human genome, include ribosomal RNAs (rRNAs), short ncRNAs, circRNAs, pseudogenes, and many lncRNAs [2]. For a long time, lncRNAs, circRNAs, and pseudogenes were regarded as useless components in the genome. In 1976, scholars discovered the existence of circRNA (pathogenic single-stranded circular virus) in higher plants [3]. In 1977, the first pseudogene was discovered in the Xenopus genome [4]. In the 1990s, researchers discovered an imprinted gene, lncRNA H19, which forms the H19/IGF-2 imprinted gene group with the similarly-located insulin-like growth factor 2 [5]. At the same time, other studies showed that the lncRNA XIST can participate in the transcriptional regulation of genes on sex chromosomes [6,7]. Thus, ncRNA began receiving attention. HOTAIR, another lncRNA, was discovered in 2007. Studies have shown that it can enhance the PRC2 activity of the HOXD locus and participate in PRC2-mediated chromatin silencing [8]. In 2013, a study revealed, for the first time, that circRNA could be used as a miRNA sponge to adsorb miRNA, thereby affecting gene expression [9]. With the deepening of research, it was found that lncRNAs, circRNAs, and pseudogenes can play biological functions in immune response [10], nerve conduction [11], growth and development [11], and stress response [12]. With the help of microarray and RNA sequencing technology, people have ascertained that lncRNAs, circRNAs, and pseudogenes are involved in regulating various tumor cell biological activities [13].
It was discovered that ncRNAs contain miRNA response elements (MREs) and act as a miRNA sponge, and an increasing number of studies have shown that they participate in the formation of a complex regulatory network. The ceRNA hypothesis proposes that certain transcripts, such as lncRNAs, circRNAs, pseudogenes, and mRNAs, have MREs in common, regulating the transcription of gene expression through competitive binding of miRNAs [14]. Thus, they are each other’s ceRNA. It has been 10 years since the ceRNA hypothesis was put forward, and research on ceRNA has been steadily increasing yearly. Researchers found that the ceRNA network plays an important role in cardiovascular diseases such as myocardial hypertrophy [15,16], myocardial infarction [17,18], atherosclerosis [19,20,21,22], neurodegenerative diseases such as Alzheimer’s disease [23,24], Parkinson’s disease [25,26], Huntington’s disease [27,28], and neuroimmune diseases such as progressive muscular dystrophy and cocaine syndrome [29,30,31]. Therefore, studying the ceRNA regulatory network is of great significance in understanding the diseases’ occurrence and development, and improving clinical diagnosis, treatment methods, and prognosis.
Cancer became the main cause of death and the single most important obstacle to increasing people’s life expectancy in the 21st century. Cancer is mainly related to genetic factors [32], immune factors [33], endocrine factors and other endogenous factors, as well as living habits [34,35], environmental pollution [36], biological factors [37], and other exogenous factors. ceRNAs play an important role in cancer progression, including gastric cancer (GC), colon cancer, liver cancer, breast cancer, and lung cancer [38,39]. GC is a common cancer worldwide. Studies have found that lncRNAs, circRNAs, and pseudogenes such as ceRNAs can participate in biological behaviors such as GC proliferation, differentiation, and cell resistance. Therefore, an increasing number of studies on the ceRNA network in GC are expected to provide new ideas for understanding the mechanism of GC occurrence and development and simultaneously provide direction for finding new targets for treating GC.

2. Gastric Cancer

As the fifth-most-common cancer and the third-leading cause of cancer death worldwide, GC is a deadly digestive system disease afflicting many people. GC was responsible for over 1,000,000 new cases in 2018 and an estimated 783,000 deaths (equating to one in every 12 deaths globally) [38,40].
Global cancer statistics 2018 show that GC incidence and mortality in Asia rank first by world region. Factors that cause this disease include Helicobacter pylori infection, age, high salt intake, and low fruit and vegetable diets. Alcohol consumption and active tobacco smoking are also established risk factors [38].
However, the gold standard for GC diagnosis is endoscopic biopsy plus enhanced computed tomography. Many patients resist examination due to the insidious onset, unobtrusive symptoms, and invasive examination methods. Furthermore, since early GC has nonspecific symptoms, most GC patients are diagnosed at advanced stages, and the 5-year survival rates range between 20% and 30% [41,42].
Surgical treatment plus chemotherapy remains the first-line approach to provide a cure for GC. Despite advances in surgical techniques, radiotherapy, chemotherapy, and neoadjuvant therapy, chemotherapy resistance or drug resistance is still an important issue that needs to be faced because cancer cells will form a mechanism to counteract the effects of chemotherapy drugs, leading to more clones and aggressiveness, and eventually a poor prognosis. Chemoresistance can be inherent and acquired, and it is a multi-factor event, including dysregulation of key signaling pathways, acquired mutations, and DNA damage responses [43].
Therefore, exploring the pathogenesis and looking for key factors to guide diagnosis and treatment has always been a research focus.
The occurrence and development of GC is a multi-stage and multi-factor process, and its pathogenesis is complex. The current research shows that its occurrence is often related to abnormal transcription. This abnormality is not limited to abnormal protein-coding RNA (mRNA) levels and includes abnormalities in the regulatory ability of ncRNA in the genome. Studies have shown that the cancer stem cell (CSC) is one of the main reasons for the failure of cancer treatment. The expression of miRNAs plays an important role in the maintenance of stem/progenitor cells. The dysregulation of miRNAs in gastric cancer stem cells (GCSCs) is closely related to the occurrence and development of gastric cancer [44].

3. ceRNAs

In 2007, Ebert et al. artificially synthesized miRNA inhibitors called miRNA sponges. With an increasing number of experimental verifications and the discovery of endogenous miRNA sponges, in 2011, Salmena et al. proposed the ceRNA hypothesis for the first time. It was expounded that in addition to the traditional miRNA→RNA mode of action, there is also an RNA–miRNA–mRNA regulation mode [14,45,46,47].
Here, “ceRNA” does not refer to a specific RNA but to a brand-new mode of gene expression regulation, describing a mode of action of RNA. The mechanism of ceRNA is that when the ceRNA expression is silenced, mRNAs are transcribed and exported to the cytoplasm, where they are targeted by the miRNA-mediated silencing complex (miRNA–RISC), resulting in accelerated degradation, blocking of translation, and reduction of gene expression; Second, when the ceRNA expression is activated, there will be competition for miRNA targeting and binding to the RISC complex, reducing miRNA inhibition; the miRNA–RISC complex is isolated from the gene, resulting in increased gene expression.
ceRNAs use similar MREs to bind miRNAs, thereby indirectly regulating genes’ expression competitively. This competitive miRNA binding effect is also called miRNA sponge action. According to this theory, any RNA that contains MREs may be a ceRNA, its core is miRNAs, and its members include lncRNAs, cirRNAs, mRNAs, and pseudogenes. Among the RNAs that can be used as ceRNAs, those that regulate tumor progression play an important role [48,49].
Besides, there are multiple MREs on each mRNA so that each mRNA can have multiple miRNA pathways. Each miRNA has multiple ceRNAs, thus forming the last “many-to-many” ceRNA networks (ceRNETs). Compared with the miRNA regulation network, ceRNETs are more sophisticated and complex, involving more RNA molecules. When ceRNAs are abnormally expressed, they affect the expression of multiple target genes in the body and further influence cancer progression.
Research shows that ceRNAs play critical roles in the development and progression of cancers. Considering the complexity of the network of ceRNAs, this research is still in its infancy. At present, the most effective way to reveal the ceRNA function in cancer is to build ceRNETs first. A common research method is to obtain samples from different tissues, screen different miRNAs, lncRNAs, and mRNAs through microarray or sequencing technologies or the use of databases to collect information, screen differentially expressed RNAs, construct ceRNETs, extract key networks, and finally perform functional enrichment analysis and survival analysis to discover genes related to cancer development and prognosis [50,51,52].
The most commonly used databases are the Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) microarray datasets. Furthermore, researchers have also established some dedicated tools to facilitate the identification of ceRNA networks, including ceRDB, Linc2GO, starBase v2.0, lnCeDB, and Cupid. Details and resources are summarized in chronological order in Table 1. The functions of these tools are different. Researchers should choose according to their needs.

4. lncRNAs as ceRNAs in GC

lncRNAs are greater than 200 nucleotides in length molecules lacking obvious open reading frames, not translated into proteins, and widely transcribed in the genome of eukaryotic cells [69].
Recently, lncRNAs have become a research focus in the field of oncology. There are diverse mechanisms for lncRNAs to regulate miRNA. This article focuses on their actions as ceRNAs, where lncRNAs can play the role of endogenous "miRNA sponges" competing with mRNAs to bind the MREs of miRNAs, thereby inhibiting miRNA expression and its negative regulation of target genes, and participating in the occurrence and development of tumors, providing a new perspective for the study of tumor formation mechanisms and tumor detection methods [70,71,72,73,74].

4.1. HOTAIR

Using high-resolution chip analysis technology, scholars discovered a lncRNA transcribed from the HOXC locus in the study of 11 human fibroblasts and named it HOTAIR in 2007. HOTAIR was the first antisense transcription lncRNA to be discovered. It contains 2158 nucleotides, and its expression level in cancer tissues is higher than in normal tissues [8]. Studies have found that it functions as a ceRNA in the occurrence and development of GC, breast cancer [75], lung cancer [76], liver cancer [77], and other tumors [78,79,80], and it is also related to drug resistance [81].
In 2016, a study showed that, in GC, HOTAIR directly binds to miR-126 and inhibits its expression, thus enhancing the expression of VEGFA and PIK3R2 and activating the PI3K/AKT/MRP1 pathway. HOTAIR acts as a ceRNA to promote cisplatin resistance [82]. In 2017, scholars found that the expression of HOTAIR was negatively correlated with the expression of miR-34a. The up-regulation of miR-34a caused by the down-regulation of HOTAIR can reduce cisplatin resistance in GC. The effect of the HOTAIR/miR−34a axis on GC cells may be related to PI3K/Akt and Wnt/β-catenin signaling pathway [83]. In 2018, it was found that the expression of HOTAIR was negatively correlated with the expression of miR-217. HOTAIR inhibits the expression of miR-217 and promotes the expression of GPC5 and PTPN14 as a ceRNA. Overexpression of HOTAIR inhibited the expression of miR-217 and enhanced the resistance of GC cells to paclitaxel and adriamycin [84]. In the same year, scholars discovered that HOTAIR directly targets miR-17-5p, and PTEN is modified by HOTAIR and miR-17-5p, which affects the proliferation and apoptosis of GC cells [85]. That year a study also found that the expression of HOTAIR was negatively correlated with the expression of miR-454-3p. By inhibiting the activity of STAT3/cyclin D1, down-regulating HOTAIR to stimulate the expression of miR-454-3p could inhibit the cell growth of GC [86]. Researchers then found that HOTAIR and miR-126 negatively regulate each other, which can increase or decrease the expression of CXCR4. Highly expressed HOTAIR promotes the proliferation and metastasis of GC through the miR-126/CXCR4 axis and downstream signaling pathways [87]. In addition, miR-618 is also a direct target of HOTAIR. The silence of HOTAIR makes miR-618 spongy, thereby blocking the development of GC and inhibiting the growth of xenograft tumors in vivo [88]. In 2020, researchers discovered a negative regulatory relationship between HOTAIR and miR-1277-5p. HOTAIR regulates the growth of GC by stimulating miR-1277-5p and up-regulating COL5A1 [89]. In the same year, a study found that HOTAIR can promote the carcinogenesis of GC by regulating the levels of miRNA in cells and exosomes. Over-expressed HOTAIR induced the degradation of miR-30a or -b, thus acting as a ceRNA [90]. The latest research shows that HOTAIR and miR-148b can induce the methylation of the tumor suppressor gene PCKG10 and promote GC [91]. These data indicate that HOTAIR can promote the occurrence and development of GC in various ways and enhance the drug resistance of GC cells as a ceRNA.

4.2. XIST

XIST is located in the X chromosome’s inactive central region, affecting the activation of X-chromosome-related genes [6,7]. Studies have found that XIST is abnormally expressed in various tumors and acts as a ceRNA to mediate tumor cell proliferation, migration, invasion, and drug resistance [92,93].
lncRNA XIST is significantly up-regulated in GC tissues and cell lines, and there is a negative correlation between its expression level and that of miR-101. Down-regulating the expression of XIST can inhibit the occurrence, development, and metastasis of GC by regulating the expression of EZH2 through miR-101 [94]. Studies have found that XIST promotes cell development from the G1 phase to the S phase and protects cells from apoptosis. XIST participates in the miR-497/MACC1 axis to regulate the proliferation and invasion of GC cells [95]. In addition, the researchers found that the expression of XIST and miR-185 are negatively correlated. miR-185 can negatively regulate the expression of TGF-β1 in vitro, and XIST can be used as a ceRNA to participate in the development of GC through the miR-185/TGF-β1 axis [96]. In 2020, studies found that XIST acts as a ceRNA in GC to regulate JAK2 by competing with miR-337. Up-regulation of miR-337 can reduce the expression of JAK2, thereby inhibiting the proliferation and migration of GC cells [97]. In addition to competing with miR-337, XIST can up-regulate the expression of PXN by competitively binding miR-132, which can enhance the ability to form GC cell proliferation, and migration. In studying the relationship between XIST and cisplatin resistance in GC, researchers found that XIST and miR-let-7b levels are negatively correlated, and the interaction between the two promotes cisplatin resistance [98].

4.3. H19

As the first imprinted gene to be discovered, lncRNA H19 is located on the H19/IGF2 gene cluster of human chromosome 11p15 [5]. With the deepening of research, it was found that lncRNA H19 plays an important role in the occurrence and development of cancer. It acts as an oncogene in some tumors to mediate the tumor process, while in others it plays a role as a tumor suppressor gene [99,100,101].
Studies have found that the expression of H19 is positively correlated with the expression of miR-675. The up-regulated expression of H19 and miR-675 can promote cell proliferation and inhibit cell apoptosis. The H19/miR-675 axis promotes GC’s occurrence and development through the FADD/caspase 8/caspase 3 signaling pathway [102]. In 2018, researchers found that the expression of H19 was negatively correlated with the expression of miR-let-7c. miR-let-7c belongs to the let-7 family and functions as a tumor suppressor gene. Silencing H19 resulted in a significant increase in let-7c expression, while HER2 protein expression decreased, indicating that H19 competes with miR-let-7c as a ceRNA in GC and regulates HER2 expression [103]. In the analysis of the GC ceRNA network, scholars found that the differentially regulated miR-21 and miR-148a play an important role in coordinating the sponge activity of H19, and the overexpression of H19 may be a landmark event in gastric tumorigenesis [104]. In 2019, studies showed that H19 expression is inversely proportional to miR-22-3p expression in GC tissues, and the inhibition of Snail1 can partially reverse the cell growth and metastasis induced by miR-22-3p down-regulation. H19 promotes tumor growth and metastasis through the miR-22-3p/Snail1 signaling pathway [105]. In 2020, when analyzing the lncRNA–miRNA–mRNA network of GC, scholars found that H19, miR-29a-3p, COL3A1, COL5A2, COL1A2, and COL4A1 can form a ceRNA network. H19 stimulates miR-29a-3p to promote GC [106]. The latest research shows that knocking down the expression of H19 can promote the up-regulation of miR-138, and E2F2 can be negatively regulated by miR-138, thereby inhibiting the proliferation and invasion of GC, increasing the rate of apoptosis [107].

4.4. MALAT1

In 2003, researchers discovered a differentially expressed gene in tumor cells of patients with early-stage non-small-cell lung cancer [108]. After screening and comparison, they found that it was an alpha transcript that had been described in 1997 and is known as MALAT1 [109]. Studies have shown that MALAT1 is involved in tumor proliferation, metastasis, apoptosis, epigenetic regulation, cell signal transduction, and other processes [110,111,112]. Recently, MALAT1 has attracted more researchers’ attention due to its role as a ceRNA in GC [113].
In 2016, scholars found that MALAT1 is up-regulated in GC tissues. Knockdown of MALAT1 can negatively regulate miR-202 and significantly reduce the expression of Gli2, thereby inhibiting the proliferation of GC cells and inducing apoptosis [114]. The expression of MALAT1 is relatively high in the cancer tissues of patients with short survival and poor prognosis. MALAT1 can sponge miR-1297, and they are negatively correlated. The up-regulation of MALAT1 leads to miR-1297, thus reducing the ability to inhibit the expression of HMGB2 [115]. A 2017 study showed that the expression of MALAT1 is related to the chemoresistance of GC cells. As a ceRNA of miR-23b-3p, MALAT1 can weaken the inhibitory effect of miR-23b-3p on ATG12, leading to the chemical induction of GC cell autophagy and chemical resistance [116]. The ceRNA network shows that the differentially regulated miR-21 and miR-148a play an important role in coordinating the sponging activity of MALAT1 in GC [104]. In 2019, scholars found that MALAT1 inhibits miR-30b expression as a ceRNA in the study of chemical resistance to GC. MALAT1 enhanced autophagy-related chemical resistance of GC by inhibiting the miR-30b/ATG5 axis [117]. Research in the same year showed that MALAT1 acts as a sponge of miR-125a, and the dysregulation of the MALAT1/miR-125a axis causes IL-21R to play a carcinogenic role in GC [118]. MALAT1 can also competitively bind to miR-181a-5p, which prevents miR-181a-5p from binding to AKT3 mRNA, thereby up-regulating the level of AKT3 protein and ultimately promoting tumor growth in GC [119]. In 2020, when investigating the autophagy activity of GC tissues, researchers found that MALAT1 can inhibit the expression of miR-204 in GC cells and prevent miR-204 from down-regulating LC3B and transient receptor potential melastatin 3 (transient receptor potential melastatin 3), which activates autophagy and promotes cell proliferation [120]. MALAT1 is also negatively correlated with the expression of miR-22-3p. MiR-22-3p can negatively regulate ErbB3. The high expression of MALAT1 promotes proliferation and prevents apoptosis of GC cells by down-regulating miR-22-3p and up-regulating ErbB3. In the study of MALAT1 and miR-22-3p, it was also found that MALAT1 regulates ZFP91 through sponge miR-22-3p to enhance GC cells’ resistance to oxaliplatin (OXA) [121]. The latest research shows that hydrogen gas can inhibit the proliferation of GC cells and the expression of MALAT1 and EZH2, up-regulating the expression of miR-124-3p at the same time. It shows that the expression of MALAT1 and miR-124-3p is negatively correlated. Overexpression of MALAT1 can eliminate the effect of hydrogen [122].
In summary, some regulatory axes have been identified in the representative lncRNA-mediated ceRNETs that affect multiple hallmarks of GC progression, including proliferation, invasion, apoptosis, and migration (Figure 1 and Table 2). Studies have found that during the epithelial to mesenchymal transition (EMT) of gastric cancer, LncRNAs can act as ceRNAs to directly regulate the expression of E-cadherin and also to participate in the regulation of the expression of EMT-inducing transcription factors (EMT-TF) [123]. Further, many other lncRNAs also play the role of ceRNAs in GC. We have summarized studies on the role of lncRNAs as ceRNAs in GC during the past five years in Table 2.

5. circRNAs as ceRNAs in GC

circRNAs are closed loops in the cytoplasm, with neither a 5′cap structure nor a 3′polyadenylic acid tail structure. They were found in viroids for the first time [3]. With the development of RNA sequencing technology and in-depth research, it was found that circRNAs are widely transcribed in eukaryotes [165,166,167,168]. Compared with other linear ncRNAs, they have a high degree of conservation and stability. According to its components, they can be divided into three categories: exon circular RNAs (ecircRNAs) [169], intron circular RNAs (ciRNAs) [170], and exon–intron circular RNAs (EIciRNAs) [171], each of which has different molecular structures but have similar binding sites and regulatory functions, and provides a template for biosynthesis.
In recent years, there have been more studies on the function of circular RNAs as ceRNAs in GC. In 2017, researchers found that the expression of circNRIP1 can up-regulate the AKT1 levels in GC cells and promote cell proliferation, migration, and invasion. Up-regulation of miR-149-5p can prevent the malignant behavior caused by circNRIP1. The circNRIP1/miR-149-5p/AKT1/mTOR axis is responsible for changes in GC cells’ metabolism and promotes the development of GC [172]. In 2019, researchers discovered a new type of circRNA, has_circ_0001368. The low expression of has_circ_0001368 can promote tumor growth, and it plays a tumor suppressor effect in GC through the miR-6506-5p/FOXO3 axis [173]. In the same year, it was found that the expression of circCOL6A3 and miR-3064-5p are inversely proportional. Overexpression of circCOL6A3 promotes GC cell proliferation, migration, and apoptosis by eliminating the inhibitory effect on COL6A3 induced by miR-3064-5p [174]. Studies have found that circRNA0047905 can bind miR4516 and miR1227-5p, thereby reducing the inhibition of SERPINB5 and MMP11, activating the Akt/CREB signaling pathway, and promoting the progression of GC. Circular RNA 0047905 may act as a tumor promoter in the pathogenesis of GC [175]. TGFBR1 is the receptor of the TGF-β ligand. Studies have found that circCACTIN promotes the progression of GC by sponging miRNA-331-3p and regulating the expression of TGFBR1 mRNA [176]. In studies to confirm the function of circGRAMD1B, it was found that circGRAMD1B inhibited the proliferation, migration, and invasion of GC cells by regulating miR-130a-3p-PTEN/p21 [177]. Through bioinformatics methods, it was found that miRNA-145-5p is the target gene of circ-ZNF609. Down-regulating the expression of miRNA-145-5p can partially reverse the effect of circ-ZNF609 on the growth and migration of GC cells [178]. In 2020, researchers found that the expression of circRHOBTB3 is low in GC tissues and cell lines. circRHOBTB3 acts as a ceRNA for miR-654-3p and activates the p21 signaling pathway to inhibit GC’s growth. circRHOBTB3 is promising as a new diagnostic marker, and therapeutic target for GC [179]. circ_0006282 is a newly identified human circular RNA. Studies have found that its high expression can down-regulate miR-155, thereby activating the expression of FBXO22 and promoting the proliferation and migration of GC cells [180]. Similar to the expression of circRHOBTB3, circCCDC9 was significantly down-regulated in GC tissues and cell lines. circCCDC9 can inhibit tumor progression through the miR-6792-3p/CAV1 axis [181]. circ-MAT2B is mainly located in the cytoplasm and can act as a ceRNA to compete with miR-515-5p and increase the expression of HIF-1α [182]. circCYFIP2 is significantly up-regulated in GC tissues. Research suggests that circCYFIP2 may act as a carcinogenic circRNA to promote GC progression through the miR-1205/E2F1 axis [183]. circ_0081143 modulates the abundance of miR-497-5p by making the miR-497-5p sponge. miR-497-5p directly targets EGFR and down-regulates circ_0081143 to affect hypoxia-induced migration, invasion, and EMT of GC cells [184]. circHIPK3 is derived from the homology domain-interacting protein kinase 3 (HIPK3) gene. In GC tissues and cell lines, circHIPK3 is up-regulated. It regulates the miR-876-5p/PIK3R1 axis through the mechanism of ceRNA and mediates the proliferation, migration, and invasion of GC cells [185]. circRNA_100782 is lowly expressed in GC. Studies have found that it can be used as a molecular sponge. It can bind to miR-574-3p to regulate the expression of the tumor suppressor gene Rb. This mechanism is closely related to the proliferation and invasion of GC [186]. In the study of hsa_circ_0005556, it was found that down-regulating the expression of hsa_circ_0005556 can inhibit the growth of GC. The hsa_circ_0005556/miR-4270/MMP19 axis participates in the proliferation, migration, and invasion of GC cells through the ceRNA mechanism [187]. When circPDZD8 is highly expressed, the survival rate of GC patients is poor. circPDZD8 can up-regulate the expression of CHD9 by stimulating miR-197-5p to promote the proliferation and metastasis of GC [188]. The latest research shows that the expression level of circ-ITCH and miR-199-5p are negatively correlated in GC tissues. circ-ITCH can inhibit GC metastasis by acting as a sponge of miR-199a-5p and increasing Klotho expression [189]. So far, there are 18 miRNAs that have been identified as ceRNAs in the circRNA-mediated ceRNETs that affect multiple hallmarks of gastric progression, including proliferation, migration, invasion, and apoptosis (Figure 2 and Table 3).

6. Pseudogenes as ceRNAs in GC

Pseudogenes were once considered to be genomic fossils without bodily functions resulting from the accumulation of natural mutations of genes during biological evolution. Later, it was discovered that pseudogenes play a crucial role in gene transcription [190]. They can be used as ceRNAs to regulate gene transcription. In addition, pseudogenes can also regulate gene expression by interacting with RNA-binding proteins [191,192,193].
There are few studies on pseudogenes as ceRNAs in GC. In 2015, researchers reported for the first time that the pseudogene FER1L4 acts as a ceRNA in the proliferation of GC. Down-regulation of FER1L4 increased the abundance of miR-106a-5p, decreased PTEN mRNA and protein quantity, and promoted GC proliferation [194]. In 2017, a study found that the pseudogene PTENP1 of PTEN can be used as a ceRNA to regulate the expression of PTEN together with miR-106b/miR-93 [195]. The up-regulated expression of PTENP1 can inhibit the proliferation, metastasis, and invasion of GC cells. In the latest study, it was found that GBAP1 can competitively bind to miR-212-3p, promote GBA expression, and participate in GC development [196].

7. Conclusions

In summary, GC is a common gastrointestinal cancer with an insidious onset, and patients are often in the middle or late stage when they are diagnosed. It is important to understand the molecular mechanism of GC and to explore effective detection and treatment strategies.
The role of ncRNAs in tumors has been a hot spot in oncology research recently. The miRNA mechanism in tumors is now relatively clear, and lncRNAs, circRNAs, and pseudogenes have entered people’s fields of vision. Evidence shows that ceRNAs play an important regulatory role in GC. So far, researchers have established some RNA–miRNA–mRNA regulatory axes [197,198,199,200]. With the effective use of advanced bioinformatics tools, researchers can systematically construct more regulatory networks, and the identification of GC-related ceRNA networks should become more efficient and accurate. Some lncRNAs, circRNAs, and pseudogenes are found to act as ceRNAs. Studies showed that lncRNAs, circRNAs, and pseudogenes could promote the occurrence and development of tumors, inhibit tumor progression and metastasis, and regulate the sensitivity of tumor cells to chemotherapeutic drugs. However, the database of lncRNAs, circRNAs, and pseudogenes is not yet perfect.
Because studies usually use transfected oligonucleotides or expression vectors, there is a risk that the transfected oligonucleotide inhibitors (antagomir and miRNA sponge) may be collected by lysosomes and cannot cause miRNA activity. It is difficult to directly measure the potential activity of the introduced miRNAs. The current verification experiments are usually untested at the physiological level, artificially providing high quantification after the whole cell is lysed. Thus, the technologies to verify the effect of ceRNAs on target genes at the protein and RNA levels require a rigorous evaluation and should be complemented by studies in animal models to discover additional genes involved in cancer.
Moreover, the map of the complex lncRNA, circRNA, and pseudogene regulatory networks needs to be further improved and supplemented. However, researchers have mainly focused on a single axis or a single binding partner, and there is no uniform naming principle for lncRNAs, circRNAs, and pseudogenes. The secondary and indirect interactions may also affect the occurrence and development of GC and drug resistance. Therefore, further research should also pay attention to the complex lncRNA, circRNA, pseudogene, miRNA, and mRNA networks. Analyzing the lncRNA-specific molecular mechanisms underlying their biological function and transforming basic research into clinical application is still an enormous challenge.

Author Contributions

J.Y. and J.L. wrote the first draft of the paper. P.Z., J.Y. and J.L. revised the paper and approved the final version for publication. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the National Natural Science Foundation, grant number 31772532.

Institutional Review Board Statement

Not applicable for this review article.

Informed Consent Statement

Not required for the review article.

Data Availability Statement

No data are available for this review article.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Abbreviations

AKTAKT serine/threotine kinase 1
AKT3AKT serine/threonine kinase 3
AMPKProtein kinase AMP-activated catalytic subunit alpha 1
ARPP19CAMP-regulated phosphoprotein 19
ATG5Autophagy-related 5
ATG12Autophagy-related 12
CAV1Caveolin 1
CBFBCore-binding factor subunit beta
CDC34Cell division cycle 34, ubiqiutin-conjugating enzyme
ceRNAsCompetitive endogenous RNAs
ceRNETsceRNA networks
CHD9Chromodomain helicase DNA-binding protein 9
ciRNAsIntron circular RNAs
COL1A2Collagen type I alpha 2 chain
COL3A1Collagen type III alpha 1 chain
COL4A1Collagen type IV alpha 1 chain
COL5A1Collagen type V alpha 1 chain
COL5A2Collagen type V alpha 2 chain
CREB1CAMP-responsive element-binding protein 1
CXCL12C-X-C motif chemokine ligand 12
CXCR4C-X-C motif chemokine receptor 4
CYLDCYLD lysine 63 deubiquitinase
CYP1B1Cytochrome P450 family 1 subfamily B member 1
DRAM2DNA-damage-regulated autophagy modulator 2
E2F1E2F transcription factor 1
E2F2E2F transcription factor 2
ecircRNAsExon circular RNAs
EGFRepidermal growth factor receptor
EGR2Early growth response 2
EIciRNAsExon–intron circular RNAs
EMTEpithelial to mesenchymal transition
EMT-TFEMT-inducing transcription factor
ErbB3Erb-B2-receptor tyrosine kinase 3
EZH2Enhancer of zeste 2 polycomb-repressive complex 2 subunit
FADDFas-associated via death domain
FBXO22F-box protein 22
FOXK1Forkhead box K1
FOXO3Forkhead box O3
FOXO6Forkhead box O6
GBAGlucosylceramidase beta
GCGastric cancer
GEOGene Expression Omnibus microarray datasets
Gli2GLI family zinc finger 2
GPC5Glypican-5
H19H19-imprinted maternally-expressed transcript
HER2Erb-B2-receptor tyrosine kinase 2
HIF-1αHypoxia-inducible factor 1 subunit alpha
HIPK3Homeodomain-interacting protein kinase 3
HMGB2High-mobility group box 2
HOTAIRHOX transcript antisense RNA
hTERTHuman telomerase reverse transcriptase
IGF2Insulin-like growth factor 2
IL-21RInterleukin 21 Receptor
JAK2Janus kinase 2
KLF4Kruppel-like Factor 4
LC3BMicrotubule-associated protein 1 light chain 3 beta
LMX1ALIM homeobox transcription factor 1 alpha
lncRNAsLong non-coding RNAs
MACC1MET transcriptional regulator MACC1
MALAT1Metastasis-associated lung adenocarcinoma transcript 1
MCL-1MCL1 apoptosis regulator, BCL2 family member
MEF2DMyocyte enhancer factor 2D
miRNA–RISCmiRNA-mediated silencing complex
miRNAsMicroRNAs
MMP11Matrix metallopeptidase 11
MMP19Matrix metallopeptidase 19
MREmiRNA response element
mRNAsMessenger RNAs
MT2AMetallothionein 2A
mTORMechanistic target of rapamycin kinase
NET1Neuroepithelial cell transforming 1
OCT1POU class 2 homeobox 1
PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
PIK3R1Phosphoinositide-3-kinase regulatory subunit 1
PIK3R2Phosphoinositide-3-kinase regulatory subunit 2
PCDHProtocadherin 10
PDK1Pyruvate dehydrogenase kinase 1
PDL1CD274 molecule
PRC2Polycomb repressive complex 2
PRL-3Protein tyrosine phosphatase 4A3
PTENPhosphatase and tensin homolog
PTPN14Protein tyrosine phosphatase non-receptor type 14
PXNPaxillin
SATB1SATB homeobox 1
SDAD1SDA1 domain-containing 1
SERPINB5Serpin family B member 5
SHOX2Short stature homeobox 2
Snail1Snail family transcriptional repressor 1
STAT3Signal transducer and activator of transcription 3
TCGACancer Genome Atlas database
TGF-β1Transforming growth factor beta 1
TGF-β2Transforming growth factor beta 2
TGFBR1Transforming growth factor beta receptor 1
USF1Upstream transcription factor 1
VEGFAVascular endothelial growth factor A
XISTX inactive specific transcript
ZEB2Zinc finger E-box-binding homeobox 2
ZFP91ZFP91 zinc finger protein, atypical E3 ubiquitin ligase

References

  1. Gezer, U.; Özgür, E.; Cetinkaya, M.; Işin, M.; Dalay, N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol. Int. 2014, 38, 1076–1079. [Google Scholar] [CrossRef] [PubMed]
  2. Chan, J.J.; Tay, Y. Noncoding RNA: RNA Regulatory Networks in Cancer. Int. J. Mol. Sci. 2018, 19, 1310. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Sanger, H.L.; Klotz, G.; Riesner, D.; Gross, H.J.; Kleinschmidt, A.K. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl. Acad. Sci. USA 1976, 73, 3852–3856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Jacq, C.; Miller, J.; Brownlee, G. A pseudogene structure in 5S DNA of Xenopus laevis. Cell 1977, 12, 109–120. [Google Scholar] [CrossRef]
  5. Brannan, C.I.; Dees, E.C.; Ingram, R.S.; Tilghman, S.M. The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 1990, 10, 28–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Brown, C.; Ballabio, A.; Rupert, J.L.; LaFreniere, R.G.; Grompe, M.; Tonlorenzi, R.; Willard, H.F. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nat. Cell Biol. 1991, 349, 38–44. [Google Scholar] [CrossRef] [PubMed]
  7. Brown, C.; Hendrich, B.; Rupert, J.L.; Lafrenière, R.G.; Xing, Y.; Lawrence, J.; Willard, H.F. The human XIST gene: Analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 1992, 71, 527–542. [Google Scholar] [CrossRef]
  8. Rinn, J.; Kertesz, M.; Wang, J.; Squazzo, S.L.; Xu, X.; Brugmann, S.A.; Goodnough, L.H.; Helms, J.A.; Farnham, P.J.; Segal, E.; et al. Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs. Cell 2007, 129, 1311–1323. [Google Scholar] [CrossRef] [Green Version]
  9. Hansen, T.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nat. Cell Biol. 2013, 495, 384–388. [Google Scholar] [CrossRef]
  10. Hu, G.; Tang, Q.; Sharma, S.; Yu, F.; Escobar, T.M.; Muljo, S.; Zhu, J.; Zhao, K. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat. Immunol. 2013, 14, 1190–1198. [Google Scholar] [CrossRef] [Green Version]
  11. Feng, J.; Bi, C.; Clark, B.S.; Mady, R.; Shah, P.; Kohtz, J.D. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultra-conserved region and functions as a Dlx-2 transcriptional coactivator. Genes. Dev. 2006, 20, 1470–1484. [Google Scholar] [CrossRef] [Green Version]
  12. Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T. A large noncoding RNA is a marker for murine hepatocellular carci-nomas and a spectrum of human carcinomas. Oncogene 2007, 26, 851–858. [Google Scholar] [CrossRef] [Green Version]
  13. Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and Functions of Long Noncoding RNAs. Cell 2009, 136, 629–641. [Google Scholar] [CrossRef] [Green Version]
  14. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? Cell 2011, 146, 353–358. [Google Scholar] [CrossRef] [Green Version]
  15. Wang, K.; Liu, F.; Zhou, L.-Y.; Long, B.; Yuan, S.-M.; Wang, Y.; Liu, C.-Y.; Sun, T.; Zhang, X.-J.; Li, P.-F. The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting miR-489. Circ. Res. 2014, 114, 1377–1388. [Google Scholar] [CrossRef] [Green Version]
  16. Lai, Y.; He, S.; Ma, L.; Lin, H.; Ren, B.; Ma, J.; Zhu, X.; Zhuang, S. HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Mol. Cell. Biochem. 2017, 432, 179–187. [Google Scholar] [CrossRef]
  17. Wang, K.; Liu, C.-Y.; Zhou, L.-Y.; Wang, J.; Wang, M.; Zhao, B.; Zhao, W.-K.; Jian-Xun, W.; Yan-Fang, Z.; Zhang, X.-J.; et al. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat. Commun. 2015, 6, 6779. [Google Scholar] [CrossRef] [Green Version]
  18. Zhao, Z.-H.; Hao, W.; Meng, Q.-T.; Du, X.-B.; Lei, S.-Q.; Xia, Z.-Y. Long non-coding RNA MALAT1 functions as a mediator in cardioprotective effects of fentanyl in myocardial ischemia-reperfusion injury. Cell Biol. Int. 2017, 41, 62–70. [Google Scholar] [CrossRef]
  19. Shan, K.; Jiang, Q.; Wang, X.-Q.; Wang, Y.-N.-Z.; Yang, H.; Yao, M.-D.; Liu, C.; Li, X.-M.; Yao, J.; Liu, B.; et al. Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis. 2016, 7, e2248. [Google Scholar] [CrossRef]
  20. Lin, Z.; Ge, J.; Wang, Z.; Ren, J.; Wang, X.; Xiong, H.; Gao, J.; Zhang, Y.; Zhang, Q. Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci. Rep. 2017, 7, 42498. [Google Scholar] [CrossRef]
  21. Johnson, B.D.; Kip, K.E.; Marroquin, O.C.; Ridker, P.M.; Kelsey, S.F.; Shaw, L.J.; Pepine, C.J.; Sharaf, B.; Bairey Merz, C.N.; Sopko, G. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109, 726–732. [Google Scholar] [CrossRef] [Green Version]
  22. Thompson, J.C.; Wilson, P.G.; Shridas, P.; Ji, A.; de Beer, M.; de Beer, F.C.; Webb, N.R.; Tannock, L.R. Serum amyloid A3 is pro-atherogenic. Atherosclerosis 2018, 268, 32–35. [Google Scholar] [CrossRef]
  23. Fotuhi, S.N.; Khalaj-Kondori, M.; Feizi, M.A.H.; Talebi, M. Long Non-coding RNA BACE1-AS May Serve as an Alzheimer’s Disease Blood-Based Biomarker. J. Mol. Neurosci. 2019, 69, 351–359. [Google Scholar] [CrossRef]
  24. Zeng, T.; Ni, H.; Yu, Y.; Zhang, M.; Wu, M.; Wang, Q.; Wang, L.; Xu, S.; Xu, Z.; Xu, C.; et al. BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs. J. Chem. Neuroanat. 2019, 98, 87–96. [Google Scholar] [CrossRef]
  25. Lin, D.; Liang, Y.; Jing, X.; Chen, Y.; Lei, M.; Zeng, Z.; Zhou, T.; Wu, X.; Peng, S.; Zheng, D.; et al. Microarray analysis of an synthetic α-synuclein induced cellular model reveals the expression profile of long non-coding RNA in Parkinson’s disease. Brain Res. 2018, 1678, 384–396. [Google Scholar] [CrossRef] [PubMed]
  26. Liu, W.; Zhang, Q.; Zhang, J.; Pan, W.; Zhao, J.; Xu, Y. Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease. Cell Biosci. 2017, 7, 19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Chanda, K.; Das, S.; Chakraborty, J.; Bucha, S.; Maitra, A.; Chatterjee, R.; Mukhopadhyay, D.; Bhattacharyya, N.P. Altered Levels of Long NcRNAs Meg3 and Neat1 in Cell and Animal Models of Huntington’s Disease. RNA Biol. 2018, 15, 1348–1363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. West, J.; Davis, C.; Sunwoo, H.; Simon, M.D.; Sadreyev, R.I.; Wang, P.I.; Tolstorukov, M.Y.; Kingston, R.E. The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites. Mol. Cell 2014, 55, 791–802. [Google Scholar] [CrossRef] [Green Version]
  29. Cesana, M.; Cacchiarelli, D.; Legnini, I.; Santini, T.; Sthandier, O.; Chinappi, M.; Tramontano, A.; Bozzoni, I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147, 358–369. [Google Scholar] [CrossRef] [Green Version]
  30. Twayana, S.; Legnini, I.; Cesana, M.; Cacchiarelli, D.; Morlando, M.; Bozzoni, I. Biogenesis and function of non-coding RNAs in muscle differentiation and in Duchenne muscular dystrophy. Biochem. Soc. Trans. 2013, 41, 844–849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Arancio, W.; Giordano, C.; Pizzolanti, G. A ceRNA analysis on LMNA gene focusing on the Hutchinson-Gilford progeria syndrome. J. Clin. Bioinform. 2013, 3, 2. [Google Scholar] [CrossRef] [Green Version]
  32. Morin, P.J. Colorectal cancer: The APC-lncRNA link. J. Clin. Investig. 2019, 129, 503–505. [Google Scholar] [CrossRef] [Green Version]
  33. Vangipuram, R.; Tyring, S.K. AIDS-Associated Malignancies. In Cancer Treatment and Research; Springer: Cham, Switzerland, 2019; Volume 177, pp. 1–21. [Google Scholar] [CrossRef]
  34. Subramani, R.; Nandy, S.B.; Pedroza, D.A.; Lakshmanaswamy, R. Role of Growth Hormone in Breast Cancer. Endocrinology 2017, 158, 1543–1555. [Google Scholar] [CrossRef] [Green Version]
  35. Zaridze, D.; Borisova, E.; Maximovitch, D.; Chkhikvadze, V. Alcohol Consumption, Smoking and Risk of Gastric Cancer: Case—Control Study from Moscow, Russia. Cancer Causes Control 2000, 11, 363–371. [Google Scholar] [CrossRef]
  36. Xing, D.F.; Xu, C.D.; Liao, X.Y.; Xing, T.Y.; Cheng, S.P.; Hu, M.G.; Wang, J.X. Spatial association between outdoor air pollution and lung cancer incidence in China. BMC Public Health 2019, 19, 1377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Catalano, V.; Labianca, R.; Beretta, G.D.; Gatta, G.; de Braud, F.; Van Cutsem, E. Gastric cancer. Crit. Rev. Oncol. Hematol. 2009, 71, 127–164. [Google Scholar] [CrossRef]
  38. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
  39. Paraskevopoulou, M.D.; Georgakilas, G.; Kostoulas, N.; Reczko, M.; Maragkakis, M.; Dalamagas, T.M.; Hatzigeorgiou, A.G. DIANA-LncBase: Experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 2013, 41, D239–D245. [Google Scholar] [CrossRef]
  40. Smyth, E.C.; Nilsson, M.; Grabsch, H.I.; van Grieken, N.C.; Lordick, F. Gastric cancer. Lancet 2020, 396, 635–648. [Google Scholar] [CrossRef]
  41. Del Arco, C.D.; Medina, L.O.; Muñoz, L.E.; Heras, S.G.G.D.L.; Aceñero, M.J.F. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histol. Histopathol. 2021, 18309. [Google Scholar]
  42. Markar, S.R.; Lagergren, J.; Hanna, G.B. Research protocol for a diagnostic study of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer. BMJ Open 2016, 6, e009139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Tan, Z. Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review. Med. Sci. Monit. 2019, 25, 3537–3541. [Google Scholar] [CrossRef] [PubMed]
  44. Ruggieri, V.; Russi, S.; Zoppoli, P.; La Rocca, F.; Angrisano, T.; Falco, G.; Calice, G.; Laurino, S. The Role of MicroRNAs in the Regulation of Gastric Cancer Stem Cells: A Meta-Analysis of the Current Status. J. Clin. Med. 2019, 8, 639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4, 721–726. [Google Scholar] [CrossRef]
  46. Arvey, A.; Larsson, E.; Sander, C.; Leslie, C.S.; Marks, D.S. Target mRNA abundance dilutes microRNA and siRNA activity. Mol. Syst. Biol. 2010, 6, 363. [Google Scholar] [CrossRef]
  47. Ebert, M.S.; Sharp, P.A. Emerging Roles for Natural MicroRNA Sponges. Curr. Biol. 2010, 20, R858–R861. [Google Scholar] [CrossRef] [Green Version]
  48. Tay, Y.; Rinn, J.; Pandolfi, P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014, 505, 344–352. [Google Scholar] [CrossRef] [Green Version]
  49. Thomson, D.W.; Dinger, M.E. Endogenous microRNA sponges: Evidence and controversy. Nat. Rev. Genet. 2016, 17, 272–283. [Google Scholar] [CrossRef]
  50. Pan, H.; Guo, C.; Pan, J.; Guo, D.; Song, S.; Zhou, Y.; Xu, D. Construction of a Competitive Endogenous RNA Network and Identification of Potential Regulatory Axis in Gastric Cancer. Front. Oncol. 2019, 9, 912. [Google Scholar] [CrossRef]
  51. Liu, Q.; Zhang, W.; Wu, Z.; Liu, H.; Hu, H.; Shi, H.; Li, S.; Zhang, X. Construction of a circular RNA-microRNA-messengerRNA regulatory network in stomach adenocarcinoma. J. Cell. Biochem. 2020, 121, 1317–1331. [Google Scholar] [CrossRef]
  52. Yang, G.; Zhang, Y.; Yang, J. Identification of potentially functional CircRNA-miRNA-mRNA regulatory network in gastric carcinoma using bioinformatics analysis. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019, 25, 8777. [Google Scholar] [CrossRef]
  53. Sarver, A.L.; Subramanian, S. Competing endogenous RNA database. Bioinformation 2012, 8, 731–733. [Google Scholar] [CrossRef]
  54. Liu, K.; Yan, Z.; Li, Y.; Sun, Z. Linc2GO: A human LincRNA function annotation resource based on ceRNA hypothesis. Bioinformatics 2013, 29, 2221–2222. [Google Scholar] [CrossRef] [Green Version]
  55. Li, J.-H.; Liu, S.; Zhou, H.; Qu, L.-H.; Yang, J.-H. starBase v2. 0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42, D92–D97. [Google Scholar] [CrossRef] [Green Version]
  56. Das, S.; Ghosal, S.; Sen, R.; Chakrabarti, J. lnCeDB: Database of Human Long Noncoding RNA Acting as Competing Endogenous RNA. PLoS ONE 2014, 9, e98965. [Google Scholar] [CrossRef] [Green Version]
  57. Ghosal, S.; Das, S.; Sen, R.; Chakrabarti, J. HumanViCe: Host ceRNA network in virus infected cells in human. Front. Genet. 2014, 5, 249. [Google Scholar] [CrossRef] [Green Version]
  58. Chiu, H.-S.; Llobet-Navas, D.; Yang, X.; Chung, W.-J.; Ambesi-Impiombato, A.; Iyer, A.; Kim, H.R.; Seviour, E.G.; Luo, Z.; Sehgal, V. Cupid: Simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Res. 2015, 25, 257–267. [Google Scholar] [CrossRef] [Green Version]
  59. Wang, P.; Zhi, H.; Zhang, Y.; Liu, Y.; Zhang, J.; Gao, Y.; Guo, M.; Ning, S.; Li, X. miRSponge: A manually curated database for experimentally supported miRNA sponges and ceRNAs. Database 2015, 2015. [Google Scholar] [CrossRef] [Green Version]
  60. Bhattacharya, A.; Cui, Y. SomamiR 2.0: A database of cancer somatic mutations altering microRNA–ceRNA interactions. Nucleic Acids Res. 2016, 44, D1005–D1010. [Google Scholar] [CrossRef] [Green Version]
  61. Zheng, L.-L.; Zhou, K.-R.; Liu, S.; Zhang, D.-Y.; Wang, Z.-L.; Chen, Z.-R.; Yang, J.-H.; Qu, L.-H. dreamBase: DNA modification, RNA regulation and protein binding of expressed pseudogenes in human health and disease. Nucleic Acids Res. 2018, 46, D85–D91. [Google Scholar] [CrossRef] [Green Version]
  62. Pian, C.; Zhang, G.; Tu, T.; Ma, X.; Li, F. LncCeRBase: A database of experimentally validated human competing endogenous long non-coding RNAs. Database 2018, 2018, bay061. [Google Scholar] [CrossRef]
  63. Wang, P.; Li, X.; Gao, Y.; Guo, Q.; Wang, Y.; Fang, Y.; Ma, X.; Zhi, H.; Zhou, D.; Shen, W.; et al. LncACTdb 2.0: An updated database of experimentally supported ceRNA interactions curated from low- and high-throughput experiments. Nucleic Acids Res. 2019, 47, D121–D127. [Google Scholar] [CrossRef] [Green Version]
  64. Karagkouni, D.; Paraskevopoulou, M.D.; Tastsoglou, S.; Skoufos, G.; Karavangeli, A.; Pierros, V.; Zacharopoulou, E.; Hat-zigeorgiou, A.G. DIANA-LncBase v3: Indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res. 2020, 48, D101–D110. [Google Scholar] [CrossRef]
  65. Wang, P.; Li, X.; Gao, Y.; Guo, Q.; Ning, S.; Zhang, Y.; Shang, S.; Wang, J.; Wang, Y.; Zhi, H.; et al. LnCeVar: A comprehensive database of genomic variations that disturb ceRNA network regulation. Nucleic Acids Res. 2019, 48, D111–D117. [Google Scholar] [CrossRef]
  66. Xu, L.; Zhang, L.; Wang, T.; Wu, Y.; Pu, X.; Li, M.; Guo, Y. ExoceRNA atlas: A database of cancer ceRNAs in human blood exosomes. Life Sci. 2020, 257, 118092. [Google Scholar] [CrossRef]
  67. Cardenas, J.; Balaji, U.; Gu, J. Cerina: Systematic circRNA functional annotation based on integrative analysis of ceRNA in-teractions. Sci. Rep. 2020, 10, 1–14. [Google Scholar] [CrossRef]
  68. Wang, P.; Guo, Q.; Hao, Y.; Liu, Q.; Gao, Y.; Zhi, H.; Li, X.; Shang, S.; Guo, S.; Zhang, Y. LnCeCell: A comprehensive database of predicted lncRNA-associated ceRNA networks at single-cell resolution. Nucleic Acids Res. 2021, 49, D125–D133. [Google Scholar] [CrossRef]
  69. Quinn, J.J.; Chang, H.Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 2016, 17, 47–62. [Google Scholar] [CrossRef]
  70. Liu, S.; Song, L.; Zeng, S.; Zhang, L. MALAT1-miR-124-RBG2 axis is involved in growth and invasion of HR-HPV-positive cervical cancer cells. Tumor Biol. 2016, 37, 633–640. [Google Scholar] [CrossRef]
  71. Qi, P.; Xu, M.-D.; Shen, X.-H.; Ni, S.-J.; Huang, D.; Tan, C.; Weng, W.-W.; Sheng, W.-Q.; Zhou, X.-Y.; Du, X. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. Int. J. Cancer 2015, 137, 1269–1278. [Google Scholar] [CrossRef]
  72. Cao, W.-J.; Wu, H.-L.; He, B.-S.; Zhang, Y.-S.; Zhang, Z.-Y. Analysis of long non-coding RNA expression profiles in gastric cancer. World journal of gastroenterology: WJG 2013, 19, 3658. [Google Scholar] [CrossRef] [PubMed]
  73. Wang, Y.; Gao, S.; Liu, G.; Jia, R.; Fan, D.; Feng, X. Microarray Expression Profile Analysis of Long Non-Coding RNAs in Human Gastric Cardiac Adenocarcinoma. Cell. Physiol. Biochem. 2014, 33, 1225–1238. [Google Scholar] [CrossRef] [PubMed]
  74. Tan, J.Y.; Sirey, T.; Honti, F.; Graham, B.; Piovesan, A.; Merkenschlager, M.; Webber, C.; Ponting, C.P.; Marques, A.C. Ex-tensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse embryonic stem cells. Genome Res. 2015, 25, 655–666. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Wu, D.; Zhu, J.; Fu, Y.; Li, C.; Wu, B. LncRNA HOTAIR promotes breast cancer progression through regulating the miR-129-5p/FZD7 axis. Cancer Biomarkers 2021, 30, 203–212. [Google Scholar] [CrossRef]
  76. Li, H.; Cui, Z.; Lv, X.; Li, J.; Gao, M.; Yang, Z.; Bi, Y.; Zhang, Z.; Wang, S.; Li, S.; et al. Long Non-coding RNA HOTAIR Function as a Competing Endogenous RNA for miR-149-5p to Promote the Cell Growth, Migration, and Invasion in Non-small Cell Lung Cancer. Front. Oncol. 2020, 10, 528520. [Google Scholar] [CrossRef]
  77. Gong, X.; Zhu, Z. Long Noncoding RNA HOTAIR Contributes to Progression in Hepatocellular Carcinoma by Sponging miR-217-5p. Cancer Biother. Radiopharm. 2020, 35, 387–396. [Google Scholar] [CrossRef]
  78. Zhang, J.; Li, N.; Fu, J.; Zhou, W. Long noncoding RNA HOTAIR promotes medulloblastoma growth, migration and invasion by sponging miR-1/miR-206 and targeting YY1. Biomed. Pharmacother. 2020, 124, 109887. [Google Scholar] [CrossRef]
  79. Cui, X.; Xiao, D.; Cui, Y.; Wang, X. Exosomes-Derived Long Non-Coding RNA HOTAIR Reduces Laryngeal Cancer Radiosensitivity by Regulating microRNA-454-3p/E2F2 Axis. OncoTargets Ther. 2019, 12, 10827–10839. [Google Scholar] [CrossRef] [Green Version]
  80. Yu, G.-J.; Sun, Y.; Zhang, D.-W.; Zhang, P. Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma. Cancer Cell Int. 2019, 19, 270. [Google Scholar] [CrossRef] [Green Version]
  81. Cantile, M.; Di Bonito, M.; De Bellis, M.T.; Botti, G. Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases. Cancers 2021, 13, 570. [Google Scholar] [CrossRef]
  82. Yan, J.; Dang, Y.; Liu, S.; Zhang, Y.; Zhang, G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumor Biol. 2016, 37, 16345–16355. [Google Scholar] [CrossRef]
  83. Cheng, C.; Qin, Y.; Zhi, Q.; Wang, J.; Qin, C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int. J. Biol. Macromol. 2018, 107, 2620–2629. [Google Scholar] [CrossRef]
  84. Wang, H.; Qin, R.; Guan, A.; Yao, Y.; Huang, Y.; Jia, H.; Huang, W.; Gao, J. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J. Cell. Biochem. 2018, 119, 7226–7234. [Google Scholar] [CrossRef]
  85. Jia, J.; Zhan, D.; Li, J.; Li, Z.; Li, H.; Qian, J. The contrary functions of lnc RNA HOTAIR/miR-17-5p/PTEN axis and Shen-qifuzheng injection on chemosensitivity of gastric cancer cells. J. Cell. Mol. Med. 2019, 23, 656–669. [Google Scholar] [CrossRef] [Green Version]
  86. Jiang, D.; Li, H.; Xiang, H.; Gao, M.; Yin, C.; Wang, H.; Sun, Y.; Xiong, M. Long Chain Non-Coding RNA (lncRNA) HOTAIR Knockdown Increases miR-454-3p to Suppress Gastric Cancer Growth by Targeting STAT3/Cyclin D1. Med. Sci. Monit. 2019, 25, 1537–1548. [Google Scholar] [CrossRef]
  87. Xiao, J.; Lai, H.; Wei, S.; Ye, Z.; Gong, F.; Chen, L. lnc RNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR 4 and RhoA signaling pathway. Cancer Med. 2019, 8, 6768–6779. [Google Scholar] [CrossRef] [Green Version]
  88. Xun, J.; Wang, C.; Yao, J.; Gao, B.; Zhang, L. Long Non-Coding RNA HOTAIR Modulates KLF12 to Regulate Gastric Cancer Progression via PI3K/ATK Signaling Pathway by Sponging miR-618. OncoTargets Ther. 2019, 12, 10323–10334. [Google Scholar] [CrossRef] [Green Version]
  89. Wei, Z.; Chen, L.; Meng, L.; Han, W.; Huang, L.; Xu, A. LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A1. Gastric Cancer 2020, 23, 1018–1032. [Google Scholar] [CrossRef]
  90. Zhang, J.; Qiu, W.-q.; Zhu, H.; Liu, H.; Sun, J.-h.; Chen, Y.; Shen, H.; Qian, C.-l.; Shen, Z.-y. HOTAIR contributes to the car-cinogenesis of gastric cancer via modulating cellular and exosomal miRNAs level. Cell Death Dis. 2020, 11, 1–15. [Google Scholar] [CrossRef] [Green Version]
  91. Seo, S.I.; Yoon, J.-H.; Byun, H.J.; Lee, S.K. HOTAIR Induces Methylation of PCDH10, a Tumor Suppressor Gene, by Regulating DNMT1 and Sponging with miR-148b in Gastric Adenocarcinoma. Yonsei Med. J. 2021, 62, 118. [Google Scholar] [CrossRef]
  92. Zhao, Y.; Yu, Z.; Ma, R.; Zhang, Y.; Zhao, L.; Yan, Y.; Lv, X.; Zhang, L.; Su, P.; Bi, J. lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration. Mol. Ther. Nucleic Acids 2021, 23, 536–551. [Google Scholar] [CrossRef]
  93. Liu, T.-T.; Li, R.; Liu, X.; Zhou, X.-J.; Huo, C.; Li, J.-P.; Qu, Y.-Q. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Int. J. Med. Sci. 2021, 18, 419–431. [Google Scholar] [CrossRef]
  94. Chen, D.-l.; Ju, H.-q.; Lu, Y.-x.; Chen, L.-z.; Zeng, Z.-l.; Zhang, D.-s.; Luo, H.-y.; Wang, F.; Qiu, M.-z.; Wang, D.-s. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. J. Exp. Clin. Cancer Res. 2016, 35, 142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Ma, L.; Zhou, Y.; Luo, X.; Gao, H.; Deng, X.; Jiang, Y. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget 2016, 8, 4125–4135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Zhang, Q.; Chen, B.; Liu, P.; Yang, J. XIST promotes gastric cancer (GC) progression through TGF-β1 via targeting miR-185. J. Cell. Biochem. 2018, 119, 2787–2796. [Google Scholar] [CrossRef] [PubMed]
  97. Zheng, W.; Li, J.; Zhou, X.; Cui, L.; Wang, Y. The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337. Arab. J. Gastroenterol. 2020, 21, 199–206. [Google Scholar] [CrossRef] [PubMed]
  98. Han, X.; Zhang, H.-B.; Li, X.-D.; Wang, Z.-A. Long non-coding RNA X-inactive-specific transcript contributes to cisplatin resistance in gastric cancer by sponging miR-let-7b. Anti-Cancer Drugs 2020, 31, 1018–1025. [Google Scholar] [CrossRef]
  99. Rezaei, O.; Tamizkar, K.H.; Sharifi, G.; Taheri, M.; Ghafouri-Fard, S. Emerging Role of Long Non-Coding RNAs in the Pathobiology of Glioblastoma. Front. Oncol. 2021, 10, 3381. [Google Scholar] [CrossRef]
  100. Zhang, W.; Zhou, K.; Zhang, X.; Wu, C.; Deng, D.; Yao, Z. Roles of the H19/microRNA-675 axis in the proliferation and epithelial-mesenchymal transition of human cutaneous squamous cell carcinoma cells. Oncol. Rep. 2021, 45, 39. [Google Scholar] [CrossRef]
  101. Rolla, M.; Jawiarczyk-Przybyłowska, A.; Kolačkov, K.; Bolanowski, M. H19 in Endocrine System Tumours. Anticancer. Res. 2021, 41, 557–565. [Google Scholar] [CrossRef]
  102. Yan, J.; Zhang, Y.; She, Q.; Li, X.; Peng, L.; Wang, X.; Liu, S.; Shen, X.; Zhang, W.; Dong, Y.; et al. Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway. Cell. Physiol. Biochem. 2017, 42, 2364–2376. [Google Scholar] [CrossRef]
  103. Wei, Y.; Liu, Z.; Fang, J. H19 functions as a competing endogenous RNA to regulate human epidermal growth factor receptor expression by sequestering let-7c in gastric cancer. Mol. Med. Rep. 2017, 17, 2600–2606. [Google Scholar] [CrossRef]
  104. Arun, K.; Arunkumar, G.; Bennet, D.; Chandramohan, S.M.; Murugan, A.K.; Munirajan, A.K. Comprehensive analysis of aberrantly expressed lncRNAs and construction of ceRNA network in gastric cancer. Oncotarget 2018, 9, 18386–18399. [Google Scholar] [CrossRef]
  105. Gan, L.; Lv, L.; Liao, S. Long non-coding RNA H19 regulates cell growth and metastasis via the miR-22-3p/Snail1 axis in gastric cancer. Int. J. Oncol. 2019, 54, 2157–2168. [Google Scholar] [CrossRef]
  106. Li, J.; Wang, X.; Wang, Y.; Yang, Q. H19 promotes the gastric carcinogenesis by sponging miR-29a-3p: Evidence from lncRNA–miRNA–mRNA network analysis. Epigenomics 2020, 12, 989–1002. [Google Scholar] [CrossRef]
  107. Yu, J.; Fang, C.; Zhang, Z.; Zhang, G.; Shi, L.; Qian, J.; Xiong, J. H19 Rises in Gastric Cancer and Exerts a Tumor-Promoting Function via miR-138/E2F2 Axis. Cancer Manag. Res. 2020, 12, 13033–13042. [Google Scholar] [CrossRef]
  108. Ji, P.; Diederichs, S.; Wang, W.; Böing, S.; Metzger, R.; Schneider, P.M.; Tidow, N.; Brandt, B.; Buerger, H.; Bulk, E.; et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22, 8031–8041. [Google Scholar] [CrossRef] [Green Version]
  109. Guru, S.C.; Agarwal, S.; Manickam, P.; Olufemi, S.-E.; Crabtree, J.S.; Weisemann, J.M.; Kester, M.B.; Kim, Y.S.; Wang, Y.; Emmert-Buck, M.R.; et al. A Transcript Map for the 2.8-Mb Region Containing the Multiple Endocrine Neoplasia Type 1 Locus. Genome Res. 1997, 7, 725–735. [Google Scholar] [CrossRef] [Green Version]
  110. Jin, Y.; Feng, S.-J.; Qiu, S.; Shao, N.; Zheng, J.-H. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 3176–3184. [Google Scholar]
  111. Yong, H.; Wu, G.; Chen, J.; Liu, X.; Bai, Y.; Tang, N.; Liu, L.; Wei, J. lncRNA MALAT1 Accelerates Skeletal Muscle Cell Apoptosis and Inflammatory Response in Sepsis by Decreasing BRCA1 Expression by Recruiting EZH2. Mol. Ther. Nucleic Acids 2020, 19, 97–108. [Google Scholar] [CrossRef]
  112. Chang, H.-L.; Bamodu, O.A.; Ong, J.-R.; Lee, W.-H.; Yeh, C.-T.; Tsai, J.-T. Targeting the epigenetic non-coding RNA MA-LAT1/Wnt signaling axis as a therapeutic approach to suppress stemness and metastasis in hepatocellular carcinoma. Cells 2020, 9, 1020. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Zhang, X.; Hamblin, M.H.; Yin, K.-J. The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017, 14, 1705–1714. [Google Scholar] [CrossRef] [PubMed]
  114. Zhang, Y.; Chen, Z.; Li, M.-J.; Guo, H.-Y.; Jing, N.-C. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. Biomed. Pharmacother. 2017, 85, 264–271. [Google Scholar] [CrossRef] [PubMed]
  115. Li, J.; Gao, J.; Tian, W.; Li, Y.; Zhang, J. Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297. Cancer Cell Int. 2017, 17, 44. [Google Scholar] [CrossRef] [Green Version]
  116. Yiren, H.; Yingcong, Y.; Sunwu, Y.; Keqin, L.; XiaoChun, T.; Senrui, C.; Ende, C.; Xizhou, L.; Yanfan, C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol. Cancer 2017, 16, 174. [Google Scholar] [CrossRef] [Green Version]
  117. Xi, Z.; Si, J.; Nan, J. LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the mi-croRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int. J. Oncol. 2019, 54, 239–248. [Google Scholar]
  118. Yan, L.; Zhang, J.; Guo, D.; Ma, J.; Shui, S.-F.; Han, X.-W. IL-21R functions as an oncogenic factor and is regulated by the lncRNA MALAT1/miR-125a-3p axis in gastric cancer. Int. J. Oncol. 2018, 54, 7–16. [Google Scholar] [CrossRef]
  119. Lu, Z.; Luo, T.; Pang, T.; Du, Z.; Yin, X.; Cui, H.; Fang, G.; Xue, X. MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis. Open Biol. 2019, 9, 190095. [Google Scholar] [CrossRef] [Green Version]
  120. Shao, G.; Zhao, Z.; Zhao, W.; Hu, G.; Zhang, L.; Li, W.; Xing, C.; Zhang, X. Long non-coding RNA MALAT1 activates au-tophagy and promotes cell proliferation by downregulating microRNA-204 expression in gastric cancer. Oncol. Lett. 2020, 19, 805–812. [Google Scholar]
  121. Li, X.; Zhao, J.; Zhang, H.; Cai, J. Silencing of LncRNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Inhibits the Proliferation and Promotes the Apoptosis of Gastric Cancer Cells Through Regulating microRNA-22-3p-Mediated ErbB3. OncoTargets Ther. 2020, 13, 559–571. [Google Scholar] [CrossRef] [Green Version]
  122. Zhu, B.; Cui, H.; Xu, W. Hydrogen inhibits the proliferation and migration of gastric cancer cells by modulating lncRNA MALAT1/miR-124-3p/EZH2 axis. Cancer Cell Int. 2021, 21, 70. [Google Scholar] [CrossRef]
  123. Landeros, N.; Santoro, P.M.; Carrasco-Avino, G.; Corvalan, A.H. Competing Endogenous RNA Networks in the Epithelial to Mesenchymal Transition in Diffuse-Type of Gastric Cancer. Cancers 2020, 12, 2741. [Google Scholar] [CrossRef]
  124. Lü, M.-H.; Tang, B.; Zeng, S.; Hu, C.-J.; Xie, R.; Wu, Y.-Y.; Wang, S.-M.; He, F.-T.; Yang, S.-M. Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene 2016, 35, 3524–3534. [Google Scholar] [CrossRef]
  125. Dong, X.-Z.; Zhao, Z.-R.; Hu, Y.; Lu, Y.-P.; Liu, P.; Zhang, L. LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis. Gastric Cancer 2020, 23, 260–272. [Google Scholar] [CrossRef]
  126. Wang, Z.; Wang, Q.; Xu, G.; Meng, N.; Huang, X.; Jiang, Z.; Chen, C.; Zhang, Y.; Chen, J.; Li, A.; et al. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells. RNA Biol. 2020, 17, 1576–1589. [Google Scholar] [CrossRef]
  127. Zong, W.; Feng, W.; Jiang, Y.; Cao, Y.; Ke, Y.; Shi, X.; Ju, S.; Cong, H.; Wang, X.; Cui, M.; et al. LncRNA CTC-497E21.4 promotes the progression of gastric cancer via modulating miR-22/NET1 axis through RhoA signaling pathway. Gastric Cancer 2020, 23, 228–240. [Google Scholar] [CrossRef]
  128. Liang, Y.; Zhang, C.-D.; Zhang, C.; Dai, D.-Q. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor pro-gression and epithelial–mesenchymal transition in gastric cancer. Gastric Cancer 2020, 23, 212–227. [Google Scholar] [CrossRef]
  129. Liu, Y.; Guo, G.; Zhong, Z.; Sun, L.; Liao, L.; Wang, X.; Cao, Q.; Chen, H. Long non-coding RNA FLVCR1-AS1 sponges miR-155 to promote the tumorigenesis of gastric cancer by targeting c-Myc. Am. J. Transl. Res. 2019, 11, 793–805. [Google Scholar]
  130. Liu, X.; Jiao, T.; Wang, Y.; Su, W.; Tang, Z.; Han, C. Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer. Minerva Med. 2016, 13, 27–34. [Google Scholar]
  131. Liu, H.-T.; Liu, S.; Liu, L.; Ma, R.-R.; Gao, P. EGR1-mediated transcription of lncRNA-HNF1A-AS1 promotes cell-cycle pro-gression in gastric cancer. Cancer Res. 2018, 78, 5877–5890. [Google Scholar]
  132. Huang, J.; Chen, Y.-X.; Zhang, B. IGF2-AS affects the prognosis and metastasis of gastric adenocarcinoma via acting as a ceRNA of miR-503 to regulate SHOX2. Gastric Cancer 2020, 23, 23–38. [Google Scholar] [CrossRef]
  133. Ma, Y.; Liu, Y.; Pu, Y.; Cui, M.; Mao, Z.; Li, Z.; He, L.; Wu, M.; Wang, J. LncRNA IGFL2-AS1 functions as a ceRNA in regulating ARPP19 through competitive binding to miR-802 in gastric cancer. Mol. Carcinog. 2020, 59, 311–322. [Google Scholar] [CrossRef]
  134. Feng, L.; Li, H.; Li, F.; Bei, S.; Zhang, X. LncRNA KCNQ1OT1 regulates microRNA-9-LMX1A expression and inhibits gastric cancer cell progression. Aging 2020, 12, 707–717. [Google Scholar] [CrossRef]
  135. Wang, J.; Wu, F.; Li, Y.; Pang, L.; Wang, X.; Kong, G.; Zhang, T.; Yu, D. KCNQ1OT1 accelerates gastric cancer progression via miR-4319/DRAM2 axis. Int. J. Immunopathol. Pharmacol. 2020, 34, 2058738420954598. [Google Scholar] [CrossRef]
  136. Hu, J.; Ni, G.; Mao, L.; Xue, X.; Zhang, J.; Wu, W.; Zhang, S.; Zhao, H.; Ding, L.; Wang, L. LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis. OncoTargets Ther. 2019, 12, 7865–7875. [Google Scholar] [CrossRef] [Green Version]
  137. Chen, X.; Chen, Z.; Yu, S.; Nie, F.; Yan, S.; Ma, P.; Chen, Q.; Wei, C.; Fu, H.; Xu, T.; et al. Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer. Clin. Cancer Res. 2018, 24, 2002–2014. [Google Scholar] [CrossRef] [Green Version]
  138. Luo, Y.; Tan, W.; Jia, W.; Liu, Z.; Ye, P.; Fu, Z.; Lu, F.; Xiang, W.; Tang, L.; Yao, L.; et al. The long non-coding RNA LINC01606 contributes to the metastasis and invasion of human gastric cancer and is associated with Wnt/β-catenin signaling. Int. J. Biochem. Cell Biol. 2018, 103, 125–134. [Google Scholar] [CrossRef]
  139. Chen, M.; Fan, L.; Zhang, S.-M.; Li, Y.; Chen, P.; Peng, X.; Liu, D.-B.; Ma, C.; Zhang, W.-J.; Zou, Z.-W.; et al. LINC01939 inhibits the metastasis of gastric cancer by acting as a molecular sponge of miR-17-5p to regulate EGR2 expression. Cell Death Dis. 2019, 10, 70. [Google Scholar] [CrossRef] [Green Version]
  140. Dong, L.; Hong, H.; Chen, X.; Huang, Z.; Wu, W.; Wu, F. LINC02163 regulates growth and epithelial-to-mesenchymal tran-sition phenotype via miR-593-3p/FOXK1 axis in gastric cancer cells. Artif. Cells Nanomed. Biotechnol. 2018, 46 (Suppl. 2), 607–615. [Google Scholar] [CrossRef] [Green Version]
  141. Zhang, C.; Ma, M.-H.; Liang, Y.; Wu, K.-Z.; Dai, D.-Q. Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro. World J. Gastrointest. Oncol. 2019, 11, 91–101. [Google Scholar] [CrossRef]
  142. Lei, K.; Liang, X.; Gao, Y.; Xu, B.; Xu, Y.; Li, Y.; Tao, Y.; Shi, W.; Liu, J. Lnc-ATB contributes to gastric cancer growth through a MiR-141-3p/TGFβ2 feedback loop. Biochem. Biophys. Res. Commun. 2017, 484, 514–521. [Google Scholar] [CrossRef] [PubMed]
  143. Zhou, Z.; Lin, Z.; He, Y.; Pang, X.; Wang, Y.; Ponnusamy, M.; Ao, X.; Shan, P.; Tariq, M.A.; Li, P.; et al. The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a. Mol. Ther. Nucleic Acids 2018, 12, 405–419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Sun, Q.; Li, J.; Li, F.; Li, H.; Bei, S.; Zhang, X.; Feng, L. LncRNA LOXL1-AS1 facilitates the tumorigenesis and stemness of gastric carcinoma via regulation of miR-708-5p/USF1 pathway. Cell Prolif. 2019, 52, e12687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  145. Li, M.; Cai, O.; Tan, S. LOXL1-AS1 Drives the Progression of Gastric Cancer via Regulating miR-142-5p/PIK3CA Axis. OncoTargets Ther. 2019, 12, 11345–11357. [Google Scholar] [CrossRef] [Green Version]
  146. Han, Y.; Wu, N.; Jiang, M.; Chu, Y.; Wang, Z.; Liu, H.; Cao, J.; Liu, H.; Xu, B.; Xie, X. Long non-coding RNA MYOSLID functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-29c-3p in gastric cancer. Cell Prolif. 2019, 52, e12678. [Google Scholar] [CrossRef] [Green Version]
  147. Miao, Z.; Guo, X.; Tian, L. The long noncoding RNA NORAD promotes the growth of gastric cancer cells by sponging miR-. Gene 2019, 687, 116–124. [Google Scholar] [CrossRef]
  148. Tao, W.; Li, Y.; Zhu, M.; Li, C.; Li, P. LncRNA NORAD promotes proliferation and inhibits apoptosis of gastric cancer by regulating miR-214/Akt/mTOR axis. OncoTargets Ther. 2019, 12, 8841. [Google Scholar] [CrossRef] [Green Version]
  149. Wang, J.; Sun, Y.; Zhang, X.; Cai, H.; Zhang, C.; Qu, H.; Liu, L.; Zhang, M.; Fu, J.; Zhang, J.; et al. Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p. Cell Death Dis. 2021, 12, 90. [Google Scholar] [CrossRef]
  150. Chen, Z.; Ju, H.; Yu, S.; Zhao, T.; Jing, X.; Li, P.; Jia, J.; Li, N.; Tan, B.; Li, Y. Prader–Willi region non-protein coding RNA 1 suppressed gastric cancer growth as a competing endogenous RNA of miR-425-5p. Clin. Sci. 2018, 132, 1003–1019. [Google Scholar] [CrossRef]
  151. Li, X.; Yan, X.; Wang, F.; Yang, Q.; Luo, X.; Kong, J.; Ju, S. Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling pathway in gastric cancer. J. Cell. Mol. Med. 2019, 23, 2920–2932. [Google Scholar] [CrossRef] [Green Version]
  152. Zhao, L.; Han, T.; Li, Y.; Sun, J.; Zhang, S.; Liu, Y.; Shan, B.; Zheng, D.; Shi, J. The IncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB J. 2016, 31, 893–903. [Google Scholar] [CrossRef] [Green Version]
  153. Cao, S.; Lin, L.; Xia, X.; Wu, H. lncRNA SPRY4-IT1 Regulates Cell Proliferation and Migration by Sponging miR-101-3p and Regulating AMPK Expression in Gastric Cancer. Mol. Ther. Nucleic Acids 2019, 17, 455–464. [Google Scholar] [CrossRef] [Green Version]
  154. Chen, Z.; Liu, H.; Yang, H.; Gao, Y.; Zhang, G.; Hu, J. The long noncoding RNA, TINCR, functions as a competing endogenous RNA to regulate PDK1 expression by sponging miR-375 in gastric cancer. OncoTargets Ther. 2017, 10, 3353–3362. [Google Scholar] [CrossRef] [Green Version]
  155. Ding, Z.; Lan, H.; Xu, R.; Zhou, X.; Pan, Y. LncRNA TP73-AS1 accelerates tumor progression in gastric cancer through reg-ulating miR-194-5p/SDAD1 axis. Pathol. Res. Pract. 2018, 214, 1993–1999. [Google Scholar] [CrossRef]
  156. Guo, J.; Li, Y.; Duan, H.; Yuan, L. LncRNA TUBA4B functions as a competitive endogenous RNA to inhibit gastric cancer progression by elevating PTEN via sponging miR-214 and miR-216a/b. Cancer Cell Int. 2019, 19, 156. [Google Scholar] [CrossRef] [Green Version]
  157. Gu, L.; Lu, L.-S.; Zhou, D.-L.; Liu, Z.-C. UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p. Cancer Med. 2018, 7, 1253–1263. [Google Scholar] [CrossRef]
  158. Yang, Z.; Shi, X.; Li, C.; Wang, X.; Hou, K.; Li, Z.; Zhang, X.; Fan, Y.; Qu, X.; Che, X.; et al. Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis. Exp. Cell Res. 2018, 368, 194–201. [Google Scholar] [CrossRef]
  159. Sun, L.; Liu, L.; Yang, J.; Li, H.; Zhang, C. SATB1 3′-UTR and lncRNA-UCA1 competitively bind to miR-495-3p and together regulate the proliferation and invasion of gastric cancer. J. Cell. Biochem. 2019, 120, 6671–6682. [Google Scholar] [CrossRef]
  160. Gong, P.; Qiao, F.; Wu, H.; Cui, H.; Li, Y.; Zheng, Y.; Zhou, M.; Fan, H. LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer. Cell Death Dis. 2018, 9, 1158. [Google Scholar] [CrossRef]
  161. Wang, C.J.; Zhu, C.C.; Xu, J.; Wang, M.; Zhao, W.Y.; Liu, Q.; Zhao, G.; Zhang, Z.Z. The lncRNA UCA1 promotes prolif-eration, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol. Cancer 2019, 18, 115. [Google Scholar] [CrossRef] [Green Version]
  162. Cao, Y.; Xiong, J.-B.; Zhang, G.-Y.; Liu, Y.; Jie, Z.-G.; Li, Z.-R. Long Noncoding RNA UCA1 Regulates PRL-3 Expression by Sponging MicroRNA-495 to Promote the Progression of Gastric Cancer. Mol. Ther. Nucleic Acids 2020, 19, 853–864. [Google Scholar] [CrossRef]
  163. Cheng, H.; Sharen, G.; Wang, Z.; Zhou, J. LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-mediated Apoptosis via miR-513a-3p in Human Gastric Cancer. Cancer Manag. Res. 2021, 13, 367–377. [Google Scholar] [CrossRef]
  164. Li, P.; Wang, L.; Li, P.; Hu, F.; Cao, Y.; Tang, D.; Ye, G.; Li, H.; Wang, D. Silencing lncRNA XIST exhibits antiproliferative and proapoptotic effects on gastric cancer cells by up-regulating microRNA-132 and down-regulating PXN. Aging 2020, 13, 14469–14481. [Google Scholar] [CrossRef]
  165. Arnberg, A.; Van Ommen, G.-J.; Grivell, L.; Van Bruggen, E.; Borst, P. Some yeast mitochondrial RNAs are circular. Cell 1980, 19, 313–319. [Google Scholar] [CrossRef]
  166. Kos, A.; Dijkema, R.; Arnberg, A.C.; Van Der Meide, P.H.; Schellekens, H. The hepatitis delta (δ) virus possesses a circular RNA. Nat. Cell Biol. 1986, 323, 558–560. [Google Scholar] [CrossRef]
  167. Capel, B.; Swain, A.; Nicolis, S.; Hacker, A.; Walter, M.; Koopman, P.; Goodfellow, P.; Lovell-Badge, R. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell 1993, 73, 1019–1030. [Google Scholar] [CrossRef]
  168. Cocquerelle, C.; Mascrez, B.; Hétuin, D.; Bailleul, B. Mis-splicing yields circular RNA molecules. FASEB J. 1993, 7, 155–160. [Google Scholar] [CrossRef] [Green Version]
  169. Zhang, X.-O.; Wang, H.-B.; Zhang, Y.; Lu, X.; Chen, L.-L.; Yang, L. Complementary Sequence-Mediated Exon Circularization. Cell 2014, 159, 134–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  170. Zhang, Y.; Zhang, X.-O.; Chen, T.; Xiang, J.-F.; Yin, Q.-F.; Xing, Y.-H.; Zhu, S.; Yang, L.; Chen, L.-L. Circular Intronic Long Noncoding RNAs. Mol. Cell 2013, 51, 792–806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  171. Li, Z.; Huang, C.; Bao, C.; Chen, L.; Lin, M.; Wang, X.; Zhong, G.; Yu, B.; Hu, W.; Dai, L. Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 2015, 22, 256. [Google Scholar] [CrossRef] [PubMed]
  172. Zhang, X.; Wang, S.; Wang, H.; Cao, J.; Huang, X.; Chen, Z.; Xu, P.; Sun, G.; Xu, J.; Lv, J.; et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol. Cancer 2019, 18, 20. [Google Scholar] [CrossRef] [Green Version]
  173. Lu, J.; Zhang, P.-Y.; Li, P.; Xie, J.-W.; Wang, J.-B.; Lin, J.-X.; Chen, Q.-Y.; Cao, L.-L.; Huang, C.-M.; Zheng, C.-H. Circular RNA hsa_circ_0001368 suppresses the progression of gastric cancer by regulating miR-6506–5p/FOXO3 axis. Biochem. Biophys. Res. Commun. 2019, 512, 29–33. [Google Scholar] [CrossRef]
  174. Sun, X.; Zhang, X.; Zhai, H.; Zhang, D.; Ma, S. A circular RNA derived from COL6A3 functions as a ceRNA in gastric cancer development. Biochem. Biophys. Res. Commun. 2019, 515, 16–23. [Google Scholar] [CrossRef]
  175. Lai, Z.; Yang, Y.; Wang, C.; Yang, W.; Yan, Y.; Wang, Z.; Xu, J.; Jiang, K. Circular RNA 0047905 acts as a sponge for mi-croRNA4516 and microRNA1227-5p, initiating gastric cancer progression. Cell Cycle 2019, 18, 1560–1572. [Google Scholar] [CrossRef]
  176. Zhang, L.; Song, X.; Chen, X.; Wang, Q.; Zheng, X.; Wu, C.; Jiang, J. Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression. Int. J. Biol. Sci. 2019, 15, 1091–1103. [Google Scholar] [CrossRef] [Green Version]
  177. Dai, X.; Guo, X.; Liu, J.; Cheng, A.; Peng, X.; Zha, L.; Wang, Z. Circular RNA circGRAMD1B inhibits gastric cancer progression by sponging miR-130a-3p and regulating PTEN and p21 expression. Aging 2019, 11, 9689–9708. [Google Scholar] [CrossRef]
  178. Liu, Z.; Pan, H.-M.; Xin, L.; Zhang, Y.; Zhang, W.-M.; Cao, P.; Xu, H.-W. Circ-ZNF609 promotes carcinogenesis of gastric cancer cells by inhibiting miRNA-145-5p expression. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 9411–9417. [Google Scholar]
  179. Deng, G.; Mou, T.; He, J.; Chen, D.; Lv, D.; Liu, H.; Yu, J.; Wang, S.; Li, G. Circular RNA circRHOBTB3 acts as a sponge for miR-654-3p inhibiting gastric cancer growth. J. Exp. Clin. Cancer Res. 2020, 39, 1. [Google Scholar] [CrossRef]
  180. He, Y.; Wang, Y.; Liu, L.; Liu, S.; Liang, L.; Chen, Y.; Zhu, Z. Circular RNA circ_0006282 Contributes to the Progression of Gastric Cancer by Sponging miR-155 to Upregulate the Expression of FBXO22. OncoTargets Ther. 2020, 13, 1001–1010. [Google Scholar] [CrossRef] [Green Version]
  181. Luo, Z.; Rong, Z.; Zhang, J.; Zhu, Z.; Yu, Z.; Li, T.; Fu, Z.; Qiu, Z.; Huang, C. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression. Mol. Cancer 2020, 19, 86. [Google Scholar] [CrossRef]
  182. Liu, J.; Liu, H.; Zeng, Q.; Xu, P.; Liu, M.; Yang, N. Circular RNA circ-MAT2B facilitates glycolysis and growth of gastric cancer through regulating the miR-515-5p/HIF-1α axis. Cancer Cell Int. 2020, 20, 171. [Google Scholar] [CrossRef] [PubMed]
  183. Lin, J.; Liao, S.; Li, E.; Liu, Z.; Zheng, R.; Wu, X.; Zeng, W. circCYFIP2 Acts as a Sponge of miR-1205 and Affects the Expression of Its Target Gene E2F1 to Regulate Gastric Cancer Metastasis. Mol. Ther. Nucleic Acids 2020, 21, 121–132. [Google Scholar] [CrossRef] [PubMed]
  184. Tang, J.; Zhu, H.; Lin, J.; Wang, H. Knockdown of Circ_0081143 Mitigates Hypoxia-Induced Migration, Invasion, and EMT in Gastric Cancer Cells Through the miR-497-5p/EGFR Axis. Cancer Biother. Radiopharm. 2021, 36, 333–346. [Google Scholar] [CrossRef] [PubMed]
  185. Li, Q.; Tian, Y.; Liang, Y.; Li, C. CircHIPK3/miR-876-5p/PIK3R1 axis regulates regulation proliferation, migration, invasion, and glutaminolysis in gastric cancer cells. Cancer Cell Int. 2020, 20, 391. [Google Scholar] [CrossRef]
  186. Xin, D.; Xin, Z. CircRNA_100782 promotes roliferation and metastasis of gastric cancer by downregulating tumor suppressor gene Rb by adsorbing miR-574-3p in a sponge form. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 8845–8854. [Google Scholar]
  187. Shen, D.; Zhao, H.; Zeng, P.; Song, J.; Yang, Y.; Gu, X.; Ji, Q.; Zhao, W. Circular RNA hsa_circ_0005556 Accelerates Gastric Cancer Progression by Sponging miR-4270 to Increase MMP19 Expression. J. Gastric Cancer 2020, 20, 300–312. [Google Scholar] [CrossRef]
  188. Xia, T.; Pan, Z.; Zhang, J. CircPDZD8 promotes gastric cancer progression by regulating CHD9 via sponging miR-197-5p. Aging 2020, 12, 19352–19364. [Google Scholar] [CrossRef]
  189. Wang, Y.; Wang, H.; Zheng, R.; Wu, P.; Sun, Z.; Chen, J.; Zhang, L.; Zhang, C.; Qian, H.; Jiang, J. Circular RNA ITCH sup-presses metastasis of gastric cancer via regulating miR-199a-5p/Klotho axis. Cell Cycle 2021, 20, 522–536. [Google Scholar] [CrossRef]
  190. Balakirev, E.S.; Ayala, F.J. Pseudogenes: Are they “junk” or functional DNA? Annu. Rev. Genet. 2003, 37, 123–151. [Google Scholar] [CrossRef] [Green Version]
  191. Han, Y.J.; Ma, S.F.; Yourek, G.; Park, Y.; Garcia, J.G.N. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 2011, 25, 2305–2312. [Google Scholar] [CrossRef]
  192. Li, C.; Zheng, L.; Xin, Y.; Tan, Z.; Zhang, Y.; Meng, X.; Wang, Z.; Xi, T. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer. FEBS Lett. 2017, 591, 991–1000. [Google Scholar] [CrossRef] [Green Version]
  193. Zhou, M.; Gao, M.; Luo, Y.; Gui, R.; Ji, H. Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model. Platelets 2018, 30, 452–459. [Google Scholar] [CrossRef]
  194. Xia, T.; Chen, S.; Jiang, Z.; Shao, Y.; Jiang, X.; Li, P.; Xiao, B.; Guo, J. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci. Rep. 2015, 5, 13445. [Google Scholar] [CrossRef]
  195. Zhang, R.; Guo, Y.; Ma, Z.; Ma, G.; Xue, Q.; Li, F.; Liu, L. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget 2017, 8, 26079–26089. [Google Scholar] [CrossRef] [Green Version]
  196. Ma, G.; Liu, H.; Du, M.; Zhang, G.; Lin, Y.; Ge, Y.; Wang, M.; Jin, G.; Zhao, Q.; Chu, H.; et al. A genetic variation in the CpG island of pseudogene GBAP1 promoter is associated with gastric cancer susceptibility. Cancer 2019, 125, 2465–2473. [Google Scholar] [CrossRef]
  197. Teng, F.; Zhang, J.X.; Chen, Y.; Shen, X.D.; Su, C.; Guo, Y.J.; Wang, P.H.; Shi, C.; Lei, M.; Cao, Y.O. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer. Mol. Oncol. 2021, 15, 1234–1255. [Google Scholar] [CrossRef]
  198. Yu, L.; Gao, Y.; Ji, B.; Feng, Z.; Li, T.; Luan, W. CTCF-induced upregulation of LINC01207 promotes gastric cancer progression via miR-1301-3p/PODXL axis. Dig. Liver Dis. 2021, 53, 486–495. [Google Scholar] [CrossRef]
  199. Ren, Z.; Liu, X.; Si, Y.; Yang, D. Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis. Artif. Cells Nanomedicine Biotechnol. 2020, 48, 572–583. [Google Scholar] [CrossRef]
  200. Guo, Y.; Sun, P.; Guo, W.; Dong, Z. Long Non-coding RNA LINC01503 Promotes Gastric Cardia Adenocarcinoma Progression via miR-133a-5p/VIM Axis and EMT Process. Dig. Dis. Sci. 2020. [Google Scholar] [CrossRef]
Genes 12 01036 g001 550
Figure 1. Representative lncRNA-mediated ceRNETs in GC.
Figure 1. Representative lncRNA-mediated ceRNETs in GC.
Genes 12 01036 g001
Genes 12 01036 g002 550
Figure 2. CircRNA-mediated ceRNETs in GC.
Figure 2. CircRNA-mediated ceRNETs in GC.
Genes 12 01036 g002
Table
Table 1. Databases and resources for ceRNAs.
Table 1. Databases and resources for ceRNAs.
Tool NameFunctionsWebsiteReference
ceRDBPredict ceRNAs for specific mRNAs targeted by miRNAs by examining the co-occurrence of miRNA response elements in the mRNAs on a genome-wide basis.http://www.oncomir.umn.edu/cefinder/ (accessed on 20 May 2021) [53]
Linc2GOMicroRNA–mRNA and microRNA–lincRNA interaction data were integrated to generate lincRNA functional annotations based on the ‘competing endogenous RNA hypothesis’.http://www.bioinfo.tsinghua.edu.cn/~liuke/Linc2GO/index.html (not available on 20 May 2021)[54]
StarBase v2.0Provide the CLIP-Seq experimentally supported miRNA-mRNA and miRNA-lncRNA interaction networks to date.http://starbase.sysu.edu.cn/ (accessed on 20 May 2021)[55]
lnCeDBA database of human lncRNAs (from GENCODE 19 version) that can potentially act as ceRNAs.http://gyanxet-beta.com/lncedb (not available on 20 May 2021)[56]
HumanViCeProvide the potential ceRNA networks in virus-infected human cells.http://gyanxet-beta.com/humanvice (not available on 20 May 2021)[57]
CupidA method for simultaneous prediction of microRNA-target interactions and their mediated competitive endogenous RNA (ceRNA) interactions.http://cupidtool.sourceforge.net/. (accessed on 20 May 2021)[58]
miRSpongeProvide an experimentally supported resource for miRNA–sponge interactions and ceRNA relationships.http://www.bio-bigdata.net/miRSponge. (not available on 20 May 2021)[59]
SomamiR 2.0A database of cancer somatic mutations in miRNA and their target sites that potentially alter the interactions between miRNAs and ceRNA including mRNAs, circRNA, and lncRNA.http://compbio.uthsc.edu/SomamiR (accessed on 20 May 2021)[60]
dreamBaseProvide insights into the transcriptional regulation, expression, functions, and mechanisms of pseudogenes as well as their roles in biological processes and diseases.http://rna.sysu.edu.cn/dreamBase (accessed on 20 May 2021)[61]
LncCeRBaseEncompasse 432 lncRNA–miRNA–mRNA interactions.http://www.insect-genome.com/LncCeRBase (accessed on 20 May 2021)[62]
LncACTdb 2.0Provide comprehensive information of competing endogenous RNAs (ceRNAs) in different species and diseases.http://www.bio-bigdata.net/LncACTdb/ (not available on 20 May 2021)[63]
DIANA-LncBase v3.0Provide correlations of miRNA–lncRNA pairs, as well as lncRNA expression profiles in a wide range of cell types and tissues.www.microrna.gr/LncBase (accessed on 20 May 2021)[64]
LnCeVarProvide genomic variations that disturb lncRNA-associated ceRNA network regulation curated from the published literature and high-throughput data sets.http://www.bio-bigdata.net/LnCeVar/ (not available on 20 May 2021)[65]
ExoceRNA atlasA repository of ceRNAs in blood exosomes.https://www.exocerna-atlas.com/exoceRNA#/ (accessed on 20 May 2021)[66]
CerinaPredict biological functions of circRNAs based on the ceRNA model.https://www.bswhealth.med/research/Pages/biostat-software.aspx. (accessed on 20 May 2021)[67]
LnCeCellDocument cellular-specific lncRNA-associated ceRNA networks for personalised characterisation of diseases based on the ‘One Cell, One World’ theory.http://www.bio-bigdata.hrbmu.edu.cn/LnCeCell/ (accessed on 20 May 2021)[68]
Table
Table 2. The mechanism of lncRNAs as ceRNAs in GC.
Table 2. The mechanism of lncRNAs as ceRNAs in GC.
LncRNAThe Mechanism of ceRNABiological FunctionsReference
BC032469miR-1207-5p/hTERTProliferation[124]
COL1A1-014miR-1273h-5p/CXCL12/CXCR4Proliferation[125]
CRALmiR-505/CYLD/AKTResistance[126]
CTC-497E21.4miR-22/NET1Proliferation, invasion[127]
DLX6-AS1miR-204-5p/OCT1Proliferation, migration, invasion[128]
FLVCR1-AS1miR-155/c-MycProliferation, invasion[129]
GAS5miR-23a/MT2AApoptosis[130]
H19miR-675/FADD/caspase 8/caspase 3Proliferation[102]
H19miR-let-7c/HER2Proliferation[103]
H19miR-22-3p/Snail1Proliferation, migration[105]
H19miR-138/E2F2Proliferation, invasion[107]
HNF1A-AS1miR-661/CDC34Proliferation[131]
HOTAIRmiR-126/VEGFA/PIK3R2Resistance[82]
HOTAIRmiR-34a/PI3K/AktResistance[83]
HOTAIRmiR-34a/Wnt/β-cateninResistance[83]
HOTAIRmiR-217/GPC5 and PTPN14Resistance[84]
HOTAIRmiR-17-5p/PTENProliferation[85]
HOTAIRmiR-454-3p/STAT3/cyclin D1Proliferation[86]
HOTAIRmiR-126/CXCR4Proliferation, migration[87]
HOTAIRmiR-618/KLF12Proliferation[88]
HOTAIRmiR-1277-5p/COL5A1Proliferation[89]
HOTAIRmiR-148b/PCDH10Proliferation[91]
IGF2-ASmiR-503/SHOX2Migration[132]
IGFL2-AS1miR-802/ARPP19Proliferation, migration[133]
KCNQ1OT1microRNA-9-LMX1AProliferation, migration, invasion[134]
KCNQ1OT1miR-4319/DRAM2Proliferation[135]
LINC00565miR-665/AKT3Proliferation[136]
LINC01234miR-204-5p/CBFBProliferation[137]
LINC01606miR-423-5p/Wnt/β-cateninMigration, invasion[138]
LINC01939miR-17-5p/EGR2Migration[139]
LINC02163miR-593-3p/FOXK1Proliferation[140]
LINC02532miR-129-5p and miR-490-5pProliferation, migration, invasion[141]
Lnc-ATBMiR-141-3p/TGFβ2Proliferation[142]
lncR-D63785miR-422a/MEF2DChemotherapy sensitivity[143]
LOXL1-AS1miR-708-5p/USF1Proliferation, migration[144]
LOXL1-AS1miR-142-5p/PIK3CAProliferation, migration[145]
MALAT1miR-202/Gli2Proliferation[114]
MALAT1miR-1297/HMGB2Proliferation, invasion[115]
MALAT1miR-23b-3/ATG12Resistance[116]
MALAT1miR-30b/ATG5Resistance[117]
MALAT1miR-125a/IL-21RProliferation, invasion[118]
MALAT1miR-181a-5p/AKT3Proliferation[119]
MALAT1miR-204/LC3BProliferation[120]
MALAT1miR-204/transient receptor potential melastatin 3Proliferation[120]
MALAT1miR-22-3p/ErbB3Proliferation[121]
MALAT1miR-22-3p/ZFP91Resistance[121]
MALAT1miR-124-3p/EZH2Proliferation[122]
MYOSLIDmiR-29c-3p/MCL-1Proliferation, inhibits apoptosis[146]
NORADmiR-608/FOXO6Proliferation[147]
NORADmiR-214/Akt/mTORProliferation, inhibits apoptosis[148]
NORADmiR-433-3p/ATG5,ATG12Resistance[149]
PWRN1miR-425-5p/PTENProliferation[150]
SLC25A5-AS1miR-19a-3p/PTEN/PI3K/AKTProliferation[151]
SNHG5miR-32/KLF4Migration[152]
SPRY4-IT1miR-101-3p/AMPKProliferation, migration[153]
TINCRmiR-375/PDK1Proliferation[154]
TP73-AS1miR-194-5p/SDAD1Proliferation, migration,[155]
TUBA4BmiR-214 and miR-216a/b/PTENProliferation, invasion[156]
UCA1miR-590-3p/CREB1Proliferation, invasion[157]
UCA1miR-7-5p/EGFRMigration[158]
UCA1miR-495-3p/SATB1proliferation and invasion[159]
UCA1miR-203/ZEB2Metastasis[160]
UCA1miR-26a/b, miR-193a, miR-214/PDL1Proliferation, migration, immune escape and inhibits apoptosis[161]
UCA1miR-495/PRL-3Proliferation, migration, invasion[162]
UCA1miR-513-3p/CYP1B1Resistance[163]
XISTmiR-101/EZH2Proliferation, migration[94]
XISTmiR-497/MACC1Proliferation, invasion[95]
XISTmiR-185/TGF-β1Growth, migration and invasion[96]
XISTmiR-337/JAK2Proliferation, migration[97]
XISTmiR-132/PXNProliferation, migration[164]
XISTXIST/miR-let-7bResistance[98]
Table
Table 3. The mechanism of circRNAs as ceRNAs in GC.
Table 3. The mechanism of circRNAs as ceRNAs in GC.
CircRNAThe Mechanism of ceRNABiological FunctionsReference
circNRIP1miR-149-5p/AKT1/mTORProliferation, migration, invasion[172]
circRNA has_circ_0001368miR-6506-5p/FOXO3Proliferation[173]
circCOL6A3miR-3064-5p/COL6A3Proliferation, migration, apoptosis[174]
circRNA0047905miR-4516/miR-1227-5p/SERPINB5/MMP11Proliferation[175]
circCACTINmiRNA-331-3p/TGFBR1Proliferation[176]
circGRAMD1BmiR-130a-3p/PTEN/p21Proliferation, migration, invasion[177]
circ-ZNF609miRNA-145-5pProliferation, migration[178]
circRHOBTB3miR-654-3p/p21Proliferation[179]
circ_0006282miR-155/FBXO22Proliferation, migration[180]
circCCDC9miR-6792-3p/CAV1Proliferation[181]
circ-MAT2BmiR-515-5p/HIF-1αProliferation[182]
circCYFIP2miR-1205/E2F1Proliferation, invasion[183]
circ_0081143miR-497-5p/EGFRmigration, invasion, EMT[184]
CircHIPK3miR-876-5p/PIK3R1Proliferation, migration, invasion[185]
circRNA_100782miR-574-3p/RbProliferation, invasion[186]
hsa_circ_0005556miR-4270/MMP19Proliferation, migration, invasion[187]
circPDZD8miR-197-5p/CHD9Proliferation, migration[188]
circ-ITCHmiR-199a-5p/KlothoMigration[189]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ye, J.; Li, J.; Zhao, P. Roles of ncRNAs as ceRNAs in Gastric Cancer. Genes 2021, 12, 1036. https://doi.org/10.3390/genes12071036

AMA Style

Ye J, Li J, Zhao P. Roles of ncRNAs as ceRNAs in Gastric Cancer. Genes. 2021; 12(7):1036. https://doi.org/10.3390/genes12071036

Chicago/Turabian Style

Ye, Junhong, Jifu Li, and Ping Zhao. 2021. "Roles of ncRNAs as ceRNAs in Gastric Cancer" Genes 12, no. 7: 1036. https://doi.org/10.3390/genes12071036

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop